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Abstract 
 
Currently, Molecular Diagnostics Laboratories in Ontario sequence coding and adjacent 
intronic regions in BRCA1 and BRCA2 in patients with a family history of breast cancer.  
At LHSC it is estimated that ~15% of patients have BRCA1 or BRCA2 variants of clinical 
significance, and ~15-20% patients have variants of unknown clinical significance 
(VUS), while the remaining patients have variants of no clinical significance, making 
patient prognosis difficult to ascertain. To elucidate VUS and improve deleterious variant 
detection, my study has three aims, 1) assess the effects of VUS on splicing using 
bioinformatics and transfection assays; 2) investigate the limitations of BRCA1 and 
BRCA2 routine sequencing in deleterious variant detection and expand deleterious variant 
detection by sequencing seven breast cancer associated genes in 21 familial breast cancer 
patients and 3) prioritize detected variants in silico for effects on: splicing, transcription 
factor binding, mRNA structure, miRNA binding and amino acids.   
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Chapter 1 Introduction 
1.1 Hereditary breast cancer and high penetrant genes BRCA1 and 
BRCA2 
 
The GLOBOCAN project, which is part of the International Agency for Cancer Research 
at the World Health Organization, estimates that over 1.3 million new cases of breast 
cancer were diagnosed worldwide in 2008, as well as 458,000 breast cancer related 
deaths, making breast cancer the most prevalent malignant cancer in women (Ferlay J. et 
al. 2008) 
1
. The American Cancer Society describes several risk factors associated with 
the development of breast cancer including: gender, environmental factors, age, family 
history of breast cancer and ethnicity.  Many research studies have been performed to 
determine the effects of these risk factors on breast cancer etiology.   Current estimates 
indicate that 5-10% of breast cancer cases are due to hereditary factors, with the 
remaining cases being due to sporadic breast cancer as a result of risk factors listed 
previously 
2
.   
 
In searching for breast cancer associated genes, Miki et al. (1994) conducted a series of 
mapping experiments on 65 expressed sequences within a 600kb region on chromosome 
17q which was previously linked to early onset breast cancer 
3,4,5
.  After extensive 
experimentation, Miki et al. (1994) identified the ~100kb breast cancer 1 early onset gene 
(BRCA1).  The following year, Wooster et al. (1995) identified a second breast cancer 
associated gene, the breast cancer 2 early onset gene (BRCA2) on chromosome 13q by 
using genetic recombination information from a cohort of families with early-onset breast 
2 
 
cancer 
6
.  Together, these two genes make up the majority of high penetrant breast cancer 
associated genes 
7
.  Numerous linkage and mutation analysis studies have shown that 
harboring a deleterious mutation in BRCA1 or BRCA2 can significantly increase the risk 
of acquiring breast cancer 
7,8
.  
1.2 Current molecular diagnostic sequencing and breast cancer 
variant databases  
 
The Molecular Diagnostics Laboratory at the London Health Sciences Centre (LHSC) 
sequences coding and adjacent intronic regions of BRCA1 and BRCA2 (-20 to +10bp 
around exons) in patients with a strong family history of breast cancer as defined on page 
two of the, “Ontario Cancer Genetic Testing Program” requisition form 
(http://www.lhsc.on.ca/lab/molegen/brca_req.pdf).  Coding and adjacent intronic 
sequencing of BRCA1 and BRCA2 revealed 158 novel variants, with patients having 
between 0 to 10 or more variants detected.  Examining these variants in the Breast Cancer 
Information Core (BIC) database (an online database compiling mutations and 
polymorphisms in breast cancer associated genes with the aim of facilitating VUS 
characterization) 
9
, revealed that 107 are listed as of unknown clinical significance or are 
not reported, 40 are listed as of no clinical significance, and 11 are listed as clinically 
significant. Currently, at LHSC it is estimated that ~15% of patients have BRCA1 or 
BRCA2 variants of clinical significance, and ~15-20% patients have variants of unknown 
clinical significance (VUS), while the remaining patients have variants of no unknown 
clinical significance.  To aid the clinical understanding of VUS, variant data should be 
converted to a standardized, consistent nomenclature for submission to a database 
3 
 
accessible to many researchers and clinicians who can perform functional and 
segregation analyses to ascertain the clinical significance of VUS.  
 
Genetic variants can be expressed in various nomenclatures.  Variant nomenclatures are 
standardized descriptions of sequence variants that include: the coordinate of the variant 
(genomic, transcript etc.), the reference nucleotide and the sequence variation.   Different 
variant cataloging databases can use different nomenclatures to describe sequence 
variants.  The Human Genome Variation Society (HGVS) 
10
 collects genomic variant 
information and associated clinical findings, and aims to foster the discovery and 
characterization of genomic variants and their phenotypic association.  HGVS and BIC 
use different variant nomenclatures.   In BIC nomenclature 
(http://research.nhgri.nih.gov/projects/bic/index.shtml), variant position numbering 
begins at the first transcribed nucleotide, whereas in HGVS nomenclature, variant 
position numbering begins at the first translated nucleotide (i.e. the “A” of the ATG start 
codon is position +1).  All nomenclatures require a DNA reference sequence from which 
to call genetic variants.  The National Center for Biotechnology Information curates a 
Reference Sequence Database (RefSeq) that houses human genomic, mRNA transcript 
and protein sequence data (as well as data for other organisms) that is used as a reference 
sequence in a variety of nomenclatures including HGVS and BIC. 
 
In the case of breast cancer related genes, after variants are detected and described in a 
particular nomenclature, researchers consult databases such as BIC to see if the variant 
has been previously reported and if its phenotypic effects are known.  In a population 
4 
 
based study conducted by Borg et al. (2010) on young women with contralateral (n=705) 
or unilateral (n=1398) breast cancer, 470 novel sequence variants were detected, 113 of 
which are deleterious mutations, 373 of which are VUS.  The Evidence-based Network 
for the Interpretation of Germline Mutant Alleles consortium (ENIGMA; 
http://enigmaconsortium.org/)
11
 was created for researchers to deposit BRCA1 and 
BRCA2 VUS’s to facilitate collaboration and variant classification.  
 
BRCA1 and BRCA2 VUS detected by the Molecular Diagnostics Laboratory at LHSC 
were catalogued in BIC and HGVS nomenclatures, as well as a clinical format different 
from HGVS that describes the amino acid position and change as well as the nucleotide 
change.  However, before variants can be submitted to the ENIGMA consortium, they 
need to be described in a consistent, standardized nomenclature, such as HGVS.  To 
facilitate VUS classification, VUS need to be submitted to the ENIGMA consortium to 
make data accessible to researchers that use functional and segregation analyses to 
investigate pathological effects of genetic variants of unknown significance.  However, 
unclassified VUS in coding and adjacent intronic regions (-20bp to +10bp around exons) 
of BRCA1 and BRCA2 may not account for all disease-causing variants in these two 
genes.   
1.3 mRNA splicing and variants in non-coding regions affecting 
disease etiology  
 
It has been estimated that 15-50% of genetic diseases are due to mRNA splicing 
abnormalities depending on the gene 
12
.  mRNA splicing is a critical step in human gene 
expression that involves many proteins working in concert to identify the exons to 
5 
 
include in mature mRNA transcript and removing intervening introns.  Canonical splicing 
sequence motifs located at intron-exon junctions, called the splicing acceptor site (3’ end 
of intron) and donor site (5’ end of intron), as well as the branch point, which is 
necessary for mRNA lariat formation, are required for accurate splicing.  However in 
humans, these sequence elements are not sufficient to recruit the spliceosome to all 
exons. Computational analysis of human mRNA transcripts conducted by Lim and Burge 
(2001) concluded that the information encoded within the canonical acceptor, donor and 
branch point splice sites is not sufficient for the spliceosome to recognize short introns 
for splicing in the human genome 
13
.  Yet, the splicing machinery is very accurate in 
identifying exons separated by large introns containing many “decoy” canonical splice 
sites, termed cryptic sites, which resemble functional acceptor and donor sites located at 
intron-exon boundaries, but are not used during splicing 
14
.  Additional cis elements 
called splicing regulatory elements can enhance or silence exon recognition by the 
spliceosome, thus influencing the final processed transcript 
14
.  Exonic splicing enhancer 
(ESE) motifs are sequences located in exons that recruit splicing regulatory proteins and 
serve as a scaffold for protein-protein interactions with components of the spliceosome, 
facilitating spliceosome assembly and promoting exon recognition 
14
.  These splicing 
enhancer proteins are from the serine-arginine (SR) rich family, and include: SRp40, 
SRp55, SC35, and splicing factor 2/alternative splicing factor (SF2/ASF), each of which 
has an N-terminal RNA-recognition domain and a C-terminal serine-arginine (SR) rich 
domain, which is responsible for protein-protein interactions with SR domains of other 
proteins, including core spliceosome components 
15
.  Each splicing enhancer binds 
unique mRNA sequences, for instance the consensus SRp40 binding sequence contains 
6 
 
an inverted repeat (GAGCAGTCGGCTC) with the potential to form a step-loop 
structure, whereas high affinity ASF/SF2 and SC35 binding sites do not display any 
predicted sequence structure 
16
.  The SF2/ASF splicing enhancer protein has been shown 
to interact with U1 and U2AF snRNPs, and facilitate acceptor and donor splice site 
recognition by the spliceosome, thus promoting exon recognition 
17
.  The SRp40 protein 
when phosphorylated, has been shown to localize to ESE elements adjacent to acceptor 
and donor sites, and facilitate acceptor and donor site recognition 
18
.   
 
Alternatively, exonic splicing silencer (ESS) motifs recruit proteins that antagonize 
splicing, such as the heteronuclear ribonucleotide proteins A/B (hnRNPA/B), which have 
been shown to interfere with both core spliceosome binding to splice sites, as well as 
splicing enhancer protein binding 
19
.  Heteronuclear ribonucleotide proteins H and F have 
been shown to bind intronic splicing enhancer (ISE) motifs and promote intron splicing 
20
.  However, when these same proteins are recruited to an exon, splicing is inhibited 
20
.  
Therefore splicing regulatory elements exist in both introns and exons and have been 
shown to modulate both alternative and constitutive splicing by recruiting splicing 
enhancer or silencer proteins to affect spliceosome assembly at canonical acceptor and 
donor splice sites 
21
.  Due to the significant role of cis splicing elements in mRNA 
splicing, genetic variants in the canonical spliceosome binding acceptor and donor sites, 
as well as the splicing branch point and splicing regulatory sites (such as: SRp40, 
ASF/SF2, SC35, SRp55 and hnRNPH) can result in disease 
22,23
.   
 
7 
 
Some variants, called “inactivating variants” can completely abolish a splice site, and 
result in no spliceosome/splicing regulatory protein binding.  Inactivating a natural donor 
or acceptor site results in the failure of the spliceosome to bind, and can result in exon 
skipping, or exon elongation/truncation if a cryptic splice site is present in close 
proximity to the inactivated site.  Variants can also weaken splice sites without fully 
inactivating them, and are called, “leaky variants”, which result in a mixture of wild type 
and aberrant mRNA transcripts.  Finally, variants can strengthen a cryptic splice site in an 
exon or intron, which can be used in place of a natural splice site depending on its 
proximity to the natural site and if it the spliceosome or splicing regulatory protein binds 
it with greater affinity than the natural site.  Cryptic splice sites are found throughout 
genes and can result in aberrant splicing if activated by a mutation.   
 
Disease causing DNA variants have been demonstrated to occur outside of exonic and 
adjacent intronic regions 
24,25
.  A study by Anczukow et al. (2012) found a BRCA2 T>G 
mutation in nine families with breast cancer that is located 594 nucleotides into intron 12 
and strengthens a cryptic donor site, resulting in the creation of a 95-nucleotide pseudo-
exon that is included in the final mRNA transcript, which alters the reading frame 
24
.  
Accurate splicing in this case was restored through antisense oligonucleotides 
suppressing cryptic exon recognition.  This variant would have gone undetected in 
routine sequencing of coding and adjacent intronic regions of BRCA1 and BRCA2.  Other 
regions not sequenced during routine sequencing that may be influential in disease 
etiology include adjacent intergenic regions, where variants within transcription factor 
binding sites could result in aberrant transcriptional regulation.  A study conducted by 
8 
 
Horn et al. (2013) 
25
 revealed that a mutation linked to familial melanoma, which is 
found in the promoter region of a gene encoding a telomerase subunit (TERT), created a 
transcription factor-binding site resulting in 2.2 fold increased gene expression in various 
cell lines through a luciferase reporter gene assay.  Therefore sequencing non-coding 
regions in BRCA1 and BRCA2 is necessary to increase deleterious variant detection in 
patients with familial breast cancer.  
1.4 Breast cancer as a polygenic disease 
 
 
Sequencing BRCA1 and BRCA2 in their entirety alone, may not be sufficient to detect all 
deleterious variants involved in familial breast cancer etiology.  Of familial breast cancer 
cases, ~13% of individuals with familial breast cancer carry identified pathogenic BRCA1 
or BRCA2 variants,
27,28,7,29
 suggesting that mutations in other genes are influential in 
breast cancer etiology.  A polygenic model of breast cancer as a complex disease may 
explain why pathogenic high-penetrant BRCA1 and BRCA2 mutations comprise only 
approximately 13% of all familial breast cancer cases 
7
.   Additionally, low to moderate 
penetrant alleles with a range of relative risks have been identified in individuals with 
breast cancer through association studies, as linkage studies have been successful mostly 
in cases of families with rarer high-penetrant monogenic mutations 
30
.  High penetrant 
deleterious variants in tumor suppressor encoding gene TP53 have also been identified in 
patients with hereditary breast cancer 
31
.  
 
Thompson et al. (2005) estimated that mutations in the ataxia telangiectasia mutated gene 
(ATM) can confer a breast cancer relative risk of approximately 2.23 (95% C.I. 1.16-4.28) 
9 
 
32
.  Several additional studies have linked low to moderate penetrant genes to breast 
cancer etiology, including: CHEK2 (odds ratio of breast cancer when harboring a 
deleterious CHEK2 variant is calculated to be 5.18 
33
), CDH1 (estimated 39-60% 
elevated risk of lobular breast cancer in individuals with a germline mutation 
34,35
) and 
PALB2 (partner and localizer of BRCA2; estimated 2.3 fold elevated risk of breast cancer 
in germline mutation carriers who do not harbor a BRCA1 or BRCA2 variant) 
36,37,29
.  
Excluding CDH1, all of these gene products are involved in the double strand DNA 
(dsDNA) break repair pathway.  Figure 1 depicts breast cancer associated gene product 
involvement in dsDNA break repair.  The serine-threonine kinase encoded by ATM 
undergoes autophosphorylation in response to DNA double stranded breaks, and goes on 
to mediate downstream phosphorylation events involved in double strand break repair, 
including the phosphorylation of cell cycle checkpoint kinase encoded by CHEK2 
(Chk2).  Phosphorylated Chk2 phosphorylates p53 (TP53), which mediates cell-cycle 
arrest.  BRCA1, BRCA2 and PALB2 proteins are part of a multi-subunit complex that 
localizes to DNA double stranded breaks resulting in strand invasion and homologous 
mediated repair.  Therefore, deleterious mutations in the genes that encode the proteins 
involved in double stranded DNA break repair can abrogate this process, and result in 
genome instability and cancer.  In addition to genes involved in the DNA double-strand 
break repair pathway, the E-cadherin encoding gene (CDH1) which is responsible for 
cell-cell adhesion, and has been shown to be associated with lobular breast cancer when 
mutated.  It has also been shown that loss of E-cadherin expression eliminates adherens 
junction formation, important in cell mobility and proliferation, and is associated with the 
transition from adenoma to carcinoma, and metastatic capacity 
38
.  Restoring E-cadherin 
10 
 
expression in cancer cell lines has been shown to restore adherens junction formation and 
exert tumor suppressive effects including reduced proliferation and motility 
39
. 
 
 
   
Figure 1. (Modified from Shuen A.Y. and Foulkes W.D. 2011
29
) Double stranded 
DNA break repair pathway.  High penetrant breast cancer associated gene products (1 
and 2), as well as low to moderate penetrant breast cancer associated gene products 
mentioned previously (3-6) are numbered above.  Dashed arrows indicate 
phosphorylation or sumoylation events.  The genes encoding the numbered gene products 
above each account for a percentage of familial breast cancer when mutated, BRCA1 (5-
10%), BRCA2 (5-10%), CHEK2 (2%), ATM (2%), PALB2 (0.4%), CDH1 (0.1%), TP53 
(0.1%) 
7
.  This figure was modified from Shuen and Foulkes (2011) 
29
 to include DNA 
repair foci and initial steps in DNA double strand break repair pathway.  Intermediate 
steps in DNA repair foci assembly have been omitted in this figure.   
11 
 
 
 
 
 
 
 
1.5 DNA targeted enrichment for downstream variant detection 
and DNA sequencing on the Illumina Genome Analyzer 
 
 
Various methods have been employed to capture specific DNA regions from a genome 
for sequencing and variant detection, including microarray-based in situ hybridization 
40,41
 and solution-based hybridization 
42
. There are several advantages of using solution-
based methods for DNA enrichment.  One is the kinetic favorability of using excess 
probe to drive hybridization to sheared DNA compared to in situ hybridization, which is 
limited by the number of probes on the array, and thus requires a larger amount of 
precious DNA sample to achieve efficient hybridization.  Therefore, solution-based 
hybridization can be more favorable because it reduces the amount of DNA sample 
required to achieve efficient enrichment.  In addition, synthesizing probes in excess 
through in vitro enzymatic reactions enables researchers to perform multiple 
hybridizations compared to on-array hybridization, in which the efficiency and 
consistency of multiple hybridizations is limited by repeated microarray stripping.  For 
these reasons, solution-based capture is a preferential means of DNA targeted enrichment 
for downstream sequencing.  A workflow for solution-based library DNA enrichment by 
Gnirke et al. (2009) 
42
 details the enzymatic steps involved in genomic DNA library and 
RNA probe preparation (Figure 2).   
 
12 
 
After DNA enrichment, samples are paired-end sequenced on the Illumina Genome 
Analyzer IIe.  Paired-end sequencing is when 36-150 nucleotides on both ends of sheared 
DNA fragments are sequenced, enabling for more stringent sequence alignment to the 
reference genome while increasing the number of times each individual nucleotide is 
sequenced, termed base coverage, thus improving variant detection accuracy. In addition 
to sequence alignment and base coverage, another aspect of variant detection accuracy is 
base quality.  The Illumina platform in this study uses a phred base quality score metric, 
which uses a logarithmic equation to estimate the probability of an incorrect base call 
during sequencing. For example, a phred base quality score of 30 is associated with a 
probability of an incorrect base call of 1 in 1000, 
43
 and can be used as a threshold for 
accurate base quality on the Illumina platform as described in their technical notes 
(http://res.illumina.com/documents/products/technotes/technote_q-scores.pdf).  On the 
Illumina platform, fluorescently labeled nucleotides containing a reversible blocking 
group are incorporated onto the sample DNA fragment one at a time, with the blocking 
group serving as a polymerization terminator.  After incorporation, individual 
fluorophores corresponding to the A/C/G/T incorporated base are excited using a laser 
and imaged.  Single nucleotide incorporation prevents base calling errors resulting from 
difficult to sequence regions, such as GC rich and repetitive regions, improving base 
calling.   
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Figure 2. (Gnirke et al. 2009) 
42
 Library preparation workflow for Illumina 
sequencing.  RNA probes (wavy lines) are transcribed in excess in vitro, incorporating 
biotinylated UTP, from PCR amplified oligonucleotides cleaved from a microarray.  
Probes are hybridized in solution to sheared, adapter ligated genomic DNA and 
subsequently eluted using streptavidin-coated magnetic beads.  Eluted DNA is PCR 
amplified and sequenced on an Illumina Genome Analyzer instrument.  
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Detected genomic variants can impact a variety of processes during the course of gene 
expression that ultimately affect gene product function.  These include the disruption of: 
transcription factor binding sites (TFBS), mRNA splicing, miRNA binding, 5’ and 3’ 
UTR mRNA structure and protein binding sites, amino acids etc.  One way to examine 
the putative effects of genetic variants on protein binding sites in silico is information 
theory.   
1.6 Prioritization of detected variants on disease etiology using 
information theory 
 
Information theory indicates the number of choices needed to select a particular variable 
from two or more alternatives 
44
.  This can be applied to genetic information.  For 
nucleotides, two questions need to be asked to determine whether a nucleotide is A, G, C 
or T (i.e. Is it a purine? Is it adenine?).  Expressing the number of binary choices needed 
to determine nucleotide identity (i.e. “information”) in “bits” results in 2 bits of 
information needed to specify a nucleic acid base.   
 
Information theory has been applied to examining protein binding site sequence 
conservation, which is a more useful tool for investigating protein binding sites than 
consensus sequences as proteins can still bind non-consensus sequences in vivo 
44
.  The 
information content (Ri) of a nucleotide at a defined position in a protein binding 
sequence can be determined from a set of aligned, experimentally validated protein 
binding sites.  The information content of a nucleotide at a particular position in an 
aligned set of protein binding sequences is inversely related to the amount of base 
uncertainty at the particular position, which is associated with the frequency of each base 
15 
 
found at that position in the set of aligned sequences.  A logarithmic equation is used to 
calculate the base uncertainty, which can then be converted to information content 
44
.  
The information content of an entire protein binding site can be calculated by summing 
the information contents of the individual positions comprising that binding site 
44
.  With 
regard to disease etiology, the information content of a mutated protein binding sequence 
can be compared to the information content of the set of aligned wild-type sequences to 
determine the likelihood of a particular mutation affecting protein binding.  The resulting 
change in information content (ΔRi) of a protein binding sequence is related to fold 
change of protein binding affinity according to 2
delta Ri
. 
45
 Therefore a 1 bit difference in 
information content of a protein binding site with and without a mutation represents a 
two-fold change in protein binding affinity.  Information theory has been used to 
prioritize variants found in protein binding sites, such as the acceptor and donor splice 
sites, for further wet-lab studies.  Mucaki et al. (2011) compared information theory 
predictions of BRCA1/2 variants in non-canonical splice sites with published mRNA 
expression data and found a total of 57 of 62 variants predicted to affect splicing using 
information theory were concordant with mRNA expression patterns 
46
.  A high success 
rate has been achieved in predicting putative splicing effects of variants in other genes as 
well, including MLH1 and MLH2 (16/17 affecting canonical splice sites validated in 
Tournier et al. study) 
47
.  
1.7 Prioritized variant validation studies 
 
 
After variants are detected, prioritized in silico for effects putative effects on WT gene 
expression using various bioinformatics tools discussed in Chapter 2.6, and Sanger 
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sequencing validated, functional assays need to be conducted to validate effects predicted 
using bioinformatics.  Variants predicted to alter transcription factor binding sites for 
example can be validated through reporter gene assays.  The familial TFBS mutation in 
TERT described in Chapter 1.3 discovered by Horn et al. (2013) 
25
 through targeted 
enrichment-based sequencing was examined using luciferase reporter gene constructs, 
one containing the promoter encoding the mutated TFBS, the other with the wild-type 
binding site, which is fused to a luciferase gene and transfected into a mammalian cell 
line.  Luciferase intensity of mutant condition is then measured using a luminometer and 
compared to wild-type control. 
 
Variants predicted to alter splicing can be examined through RNA expression analysis, 
either using tissue-specific patient RNA, or when that is unavailable, an ex vivo mini-
gene assay.  In a mini-gene assay, a putative splicing mutation is cloned into a plasmid 
harboring a “mini-gene”, a human gene fragment under CMV promoter control 
containing 2-3 exons and intervening introns, as well as two restriction enzyme sites 
where the splicing variant of interest and adjacent regions is cloned in.  The recombinant 
plasmid is then transiently transfected into a mammalian cell line along with the wild-
type control, mRNA is then extracted, reverse transcribed and PCR amplified using 
primers specific to the mini-gene cDNA to examine the effects of the variant on mRNA 
splicing through gel electrophoresis and later sequencing.   Two separate mini-gene 
plasmids containing ampicillin and neomycin resistance genes, pCAS2 and pcDNA-Dup, 
have been described by Tournier et al. (2008) 
47
 and are designed to examine effects of 
variants affecting canonical acceptor and donor splice sites, and splicing regulatory 
17 
 
elements respectively.  The cloning site in pCAS2 is within the intron separating 
SERPING1/CINH exons 1-2 of the mini-gene, where the sample exon containing the 
putative splicing-affecting variant of interest as well as ~150bp of flanking intron is 
ligated in.  The cloning site of pcDNA-Dup is within a 47bp cassette exon, which is 
located within an intron separating two exons derived from human β-globin gene, where 
a ~30bp region containing the mutated regulatory splice site is ligated in.  Due to the 
weak 3’ splice site of the cassette exon, the spliceosome will not recognize the cassette 
exon without cloning in a functional exonic splicing enhancer (ESE) element, and will 
therefore be skipped 
47
.  A schematic of pcDNA-Dup and pCAS2 mini-gene vectors is 
shown in Figure 3. 
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Figure 3.  (Adapted from Tournier et al. 2008) 
47
 A schematic of pcDNA-Dup and 
pCAS2 mini-gene vectors.  Both vectors harbor ampicillin and neomycin resistance 
genes.  Colored vertical lines indicate restriction enzyme sites used during recombinant 
plasmid construction. In pcDNA-Dup schematic, EcoRI restriction site is on the 5' end of 
the cassette exon (appears on left in image) and BamHI restriction site is on 3' end of 
cassette exon.  For pCAS2 schematic, BamHI restriction site appears at 5' end of intron 
(left-most vertical line) and MluI restriction site appears at 3' end of intron (right-most 
vertical line). A CMV promoter regulates expression of mini-genes.  
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Variants predicted to alter mRNA structure can be investigated through SHAPE analysis, 
which stands for “Selective 2’-hydroxyl acylation analyzed by primer extension” 48.  
SHAPE examines mRNA flexibility at one-base resolution by chemically modifying 
2’OH groups on ribonucleotides with a reagent such as 1-methyl-7-nitroisatoic anhydride 
(1M7).  Flexible, single stranded ribonucleotides have greater 2’OH nucleophilic 
reactivity for this reagent and are preferentially modified compared to nucleotides in 
structure.  Chemically modified, 5’ labeled sample mRNA is then digested using RNase 
R, which is capable of digesting highly structured RNA in the 3’>5’ direction, and 
recognizes chemically modified 2’OH groups as stops.  Digested mRNA encoding a 
mutation in one condition and the wild-type nucleotide in another condition, can be 
resolved using denaturing PAGE.  Position-specificity is conferred by running conditions 
alongside a “sequencing ladder”, which is generated by covalent modification of single 
stranded guanosines in 5’ labeled mRNA transcript using kethoxal reagent.  The 
transcript is subsequently digested using RNase R, which stops at modified guanosines.   
1.8 Project Aims  
 
 
Currently, Clinical Molecular Genetics Laboratories in Ontario sequence coding and 
adjacent intronic regions (-20bp and +10bp around exons) of BRCA1 and BRCA2 in 
patients with a strong family history of breast cancer.  However, as mentioned in section 
1.3, variants can occur within introns and other non-coding regions (such as transcription 
factor binding sites upstream of genes) and cause disease.  Such variants would go 
undetected by current routine diagnostic screening.  Approximately 10-20% of familial 
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breast cancer is due to pathogenic variants in BRCA1 and BRCA2 
7
.  Variants in other low 
to moderate penetrant genes that are not routinely sequenced have also been shown to 
contribute to hereditary breast cancer etiology 
7,29
.   
 
Based on the potential limitations of routine diagnostic sequencing of breast cancer 
patient DNA in identifying deleterious variants, there are three aims to this study.  The 
first aim is to 1a) convert all BRCA1 and BRCA2 variants previously detected at LHSC to 
a standardized nomenclature and submit VUS to the ENIGMA consortium; and 1b) 
assess the effects of variants on splicing using bioinformatics tools and validate 
predictions using a mini-gene assay as described in Chapter 1.7.  The second aim is to 2a) 
investigate the limitations routine sequencing of coding and adjacent intronic regions of 
BRCA1 and BRCA2 in deleterious variant detection.  This will be achieved by comparing 
the number of deleterious BRCA1 and BRCA2 variants detected by LHSC to linkage and 
mutation studies using a power analysis.  And 2b) improve variant detection by 
sequencing coding, non-coding and adjacent intergenic regions (+ 10kbp of gene) of 
seven breast cancer associated genes, including: ATM, BRCA1, BRCA2, CDH1, CHEK2, 
PALB2 and TP53.  The third aim of this study is to prioritize variants detected in 
sequencing study based on potential disruption of important mechanisms required for 
expression of these genes. We will predict variants that affect: splicing, TFBS, 5’ and 3’ 
UTR mRNA structure and RNA binding protein binding sites (RBPBS), amino acids, and 
miRNA binding sites using in silico bioinformatics tools to reduce the number of 
clinically non-significant variants and select only those potentially influential in breast 
cancer etiology. 
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It is hypothesized that 1) examining only coding and adjacent intronic regions (-20 to +10 
bp around exons) of BRCA1 and BRCA2 limits deleterious variant detection in patients 
with a family history of breast cancer.  Multiple gene sequencing will reveal variants 
potentially influential in breast cancer etiology, and 2) variants of unknown significance 
predicted to lead to splicing aberrations in silico will be validated through ex vivo 
transient transfection studies. 
1.9 Roles and responsibilities  
Coding variants of unknown significance in the LHSC breast cancer patient cohort were 
identified by the Molecular Diagnostics team (senior technologist: Alan Stuart).  Variants 
were converted to HGVS nomenclature by myself in collaboration with Alan Stuart, Dr. 
Peter Ainsworth and Dr. Peter Rogan and published to the ENIGMA consortium by Dr. 
Peter Rogan and Dr. Peter Ainsworth.  VUS were prioritized in silico for effects on 
splicing and analyzed ex vivo through transient transfection and RT-PCR by myself.   
 
The capture array used in this study to target seven breast cancer associated genes was 
designed by lab technician Eliseos Mucaki, and was synthesized by both Eliseos Mucaki 
and myself.  Purified patient genomic DNA was obtained from the Molecular Diagnostics 
Laboratory.  DNA library preparations and DNA sequencing were performed by both 
Eliseos Mucaki and myself for the first two sequencing runs, and by Eliseos Mucaki for 
the final run.  Variants were called and analyzed in silico for effects on: splicing using 
software developed by computer science student Ben Shirley by myself and Ben Shirley, 
transcription factor binding sites using a program called “Mutation Analysis” developed 
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by computer science student Coby Viner and prioritized by myself and Coby Viner, and 
5’ and 3’ UTR structure using SNPfold by Eliseos Mucaki, and RNA-binding protein 
binding sites by Eliseos Mucaki, miRNA binding and amino acid sequence using 
publically available software as described in Chapter 2.6 by myself. 
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Chapter 2. Analysis of BRCA1 and BRCA2 variants of unknown 
significance on mRNA splicing and breast cancer patient DNA 
sequencing methodology 
 
2.1 BRCA1 and BRCA2 variant nomenclature conversion 
 
Previously, all intronic BRCA1 and BRCA2 variants identified at LHSC were collated in 
BIC nomenclature 
9
 in Intervening Sequence (IVS) format, which uses an intron 
numbering system to identify the intron containing the genetic variant (for example, a 
T>C variant one nucleotide into intron 1 is described as IVS1+1T>C).  Exonic variants 
were collated in HGVS nomenclature 
10
, and a clinical format describing the amino acid 
and nucleotide change.  To create one file describing all variants in HGVS and BIC 
nomenclature for submission to the Evidence-based Network for the Interpretation of 
Germline Mutant Alleles consortium (ENIGMA; http://enigmaconsortium.org/), all 
variants were converted to HGVS cDNA nomenclature.  HGVS cDNA nomenclature 
requires: the gene name harboring the variant, the HGVS cDNA coordinate of the 
variant, and the HGVS amino acid coordinate and effect when applicable.  Conversion of 
variants to HGVS nomenclature used RefSeq database 
49
 reference sequences for BRCA1 
transcript (NM_007294.3) and BRCA2 transcript (NM_000059.3) approved by the 
ENIGMA consortium and Leiden Open Variation Database (LOVD) 
50
. 
 
To convert intronic variant coordinates in BIC nomenclature to HGVS nomenclature, a 
previously gathered list matching cDNA coordinates of the first and last nucleotide 
positions of each exon in BRCA1 and BRCA2 to the IVS numbering system, was used.   
After conversion, the reference base of all variants in HGVS format was compared to the 
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RefSeq database reference base to ensure no discrepancies emerged during coordinate 
conversion.   
 
Exonic variants in clinical format were converted to HGVS nomenclature by linking the 
amino acid change reported by the clinic to the corresponding HGVS nucleotide position 
through the BIC database, which expresses BRCA1 and BRCA2 variants, as well as amino 
acid changes, in both BIC and HGVS format.  
 
All variants were then submitted to the ENIGMA consortium.  For future in silico 
analyses, an HGVS position conversion website https://mutalyzer.nl/positionConverter 
51
 
was used to convert all variants to hg19 genomic coordinates, which is the most recent 
sequence assembly of the human genome at the time of this study 
52
.  Differences 
between BRCA1 and BRCA2 hg18 and hg19 genome builds include chromosomal 
coordinates.  Total number of exons, and amino acids encoded in the coding region 
remains the same between builds. 
2.1.1 BRCA1 and BRCA2 variant prioritization for effects on 
splicing 
 
All BRCA1 and BRCA2 variants were run through the Automated Splice Site Analysis 
(ASSA) Server 
53
 (splice.uwo.ca) to predict putative effects on splicing.  First, all variants 
were converted from HGVS to hg15 nomenclature for input into the ASSA server using a 
list previously compiled translating cDNA coordinates to corresponding hg15 genomic 
coordinates.  A 300bp window was used when examining effects of variant on splice site 
information content to look for cryptic splice sites with greater information contents than 
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the affected site that may be selected by the spliceosome or splicing enhancer/repressor 
proteins in response to a mutation. Cryptic splice sites located outside of a 300bp window 
are less likely to bind the spliceosome with a natural splice site as described in more 
detail in Chapter 2.6.  All variants were examined for information content changes in 
both canonical and regulatory splice sites including: acceptor, donor, branch point, 
SRp40, SC35, hnRNPH, SF2/ASF and SRP55.  Output was filtered to include only 
variants resulting in splice site abolishing mutations, leaky mutations, or cryptic site 
mutations with information content changes of >1 bit, corresponding to a two fold change 
in protein binding affinity 
42
, In vitro mRNA splicing assays and gene expression 
analyses have determined that a two-fold change in binding affinity is a threshold for 
detecting splicing and gene expression changes 
46,54
.  Results were further filtered based 
on: 1) the amount of information content change (ΔRi), 2) the number of splice sites 
affected by the mutation, 3) and the presence and proximity of a cryptic site of greater 
information content than an affected natural site.  After prioritization, a literature search 
of all filtered variants expressed in HGVS, BIC and hg19 nomenclatures was performed 
using: Google Scholar
TM
, PubMed, Web of Science Database (Thomson Reuters), 
Quertle
TM
 and Google
TM
 to ensure prioritized variants were classified as variants of 
unknown significance or had no published findings.   
 
After information theory based prioritization, prioritized variants were examined using 
the Human Splicing Finder version 2.4.1 
55
, an online bioinformatics tool that predicts the 
effects of mutations on canonical and regulatory splicing elements using position weight 
matrices generated from human genetic and transcript data from Ensembl 
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(www.ensembl.org).  The strength of a putative acceptor/donor site is defined as the sum 
of each nucleotide’s frequency at positions within a site plus a constant used for 
normalization 
55
.  The mean score of acceptor and donor splice sites are 86.81 (SD=6.33) 
and 87.53 (SD=8.34) respectively, strong sites are defined as having score >80, with 
weaker sites having scores between 70-80 
55
.   Prioritized variants affecting the 
information content of an ESE element were also examined using the ESEfinder tool 
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home), which is an online 
tool that uses position weight matrices of ESE motifs generated from functional 
experimental data to predict the presence of ESE elements within a submitted sequence 
56
.  The Human Splicing Finder was chosen as an additional prediction tool because the 
algorithms used to predict putative variant effects on splicing use experiment-derived 
functional canonical and regulatory splice sites from Ensembl.  A comparison between 
the Human Splicing Finder, MaxEntScan 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) 
57
 and information 
theory was conducted by Mucaki et al. (2011) for BRCA1 and BRCA2 variants with 
published mRNA expression data 
46
.  Of 36 variants examined, 22 were concordant for 
all bioinformatics methods as well as 26 of 26 variants reported to have no effect on 
splicing 
46
.  Of discordant mutations, nine were correctly predicted by information 
analysis when at least one other prediction tool did not.  BRCA1 and BRCA2 cryptic 
splice sites not predicted by information theory shown to be influential in splicing have 
been predicted by Human Splicing Finder and not MaxEntScan 
23
 and by both Human 
Splicing Finder and MaxEntScan 
58
.   In addition, putative splicing variants can be 
analyzed from a genomic context using the Human Splicing Finder but not MaxEntScan 
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or other splicing prediction tools such as the Spliceman webserver 
(http://fairbrother.biomed.brown.edu/spliceman/html/tools.html) 
59
, which have only a 
user sequence submission option, thus requiring a criteria for standardization of sequence 
input length to ensure all sites relevant in splicing are considered in predictions.  It is for 
these reasons that the Human Splicing Finder was chosen as an additional prediction tool 
for putative effects of BRCA1 and BRCA2 variants on splicing. 
 
A VUS was also selected for downstream ex vivo analysis from the BIC database, as 
described by Mucaki et al. (2011) 
46
, using the same prioritization criteria listed above. A 
workflow of variant prioritization for splicing, as well as VUS submission to ENIGMA 
consortium is displayed in Figure 4. 
 
Putative canonical leaky splicing variants were also identified using the ASSA server.   
Leaky splicing variants are defined as variants that reduce the information content of the 
natural splice site, but have a final information content of >1.6 bits, which has been used 
as a threshold for minimum functional splice site information content based on analysis 
of minimally functional splice sites 
53
.  Patient family history of hereditary breast and/or 
ovarian cancer (HBOC), which is defined as a predisposition to developing breast and/or 
ovarian cancer due to germline genetic mutations in BRCA1 or BRCA2 
60
, was obtained 
for patients with putative leaky splicing variants to examine disease penetrance.  Average 
number of 1
st
, 2
nd
 and 3
rd
 degree relatives with breast cancer for patients with each variant 
was calculated.  Also, variant rsID, as well as alternate allele population frequencies were 
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recorded as found in dbSNP.  The clinical significance of the variant as reported in BIC 
was also recorded. 
 
 
 
 
 
 
 Figure 4. Workflow of BRCA1 and BRCA2 variant in silico prioritization for effects 
on splicing.  Two files containing BRCA1 and BRCA2 variants were obtained from 
LHSC, one describing intronic variants in IVS format (BIC nomenclature) and one 
describing exonic variants (HGVS nomenclature and clinical format, as described in 
Chapter 1.2).  All variants were converted to HGVS nomenclature.  VUS were submitted 
to the ENIGMA consortium and prioritized in silico for effects on splicing using the 
ASSA server for downstream ex vivo transfection analysis. 
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2.1.2 Preparation of mini-gene construct for investigation of 
putative splicing variant, BRCA2:c.7319A>G  
 
Patient genomic DNA (gDNA) with the BRCA2:c.7319A>G variant (rs4986860, dbSNP 
alternate allele population frequency 0.007, listed in BIC as unknown clinical 
significance) was purified from a patient blood sample at LHSC using MagNA Pure 
Compact Nucleic Acid Isolation kit I (Roche, catalog#: 03 730 964 001).  This variant 
was chosen because it is predicted to create a cryptic SRp40 site in close proximity to a 
cryptic donor site in exon 14 of BRCA2.  A more detailed explanation is provided in 
Chapter 3.1. The following steps were undertaken to prepare mini-gene construct: i) PCR 
amplification of variant containing region in patient and HapMap gDNA; ii) restriction 
enzyme digestion of PCR amplified DNA products; iii) ligation of digested PCR product 
into digested, phosphatase-treated mini-gene plasmid, iv) transformation of recombinant 
mini-gene vector into DH5-α Escherichia Coli cells, v) PCR amplification of plasmid 
insert from E. coli colony, followed by plasmid purification and sequencing validation of 
insert.    
 
i) PCR amplification of variant and Wild-type (WT) region. Primers were designed to 
amplify exon 14 of BRCA2, which contains c.7319A>G, as well as 146nt of 5’ flanking 
intron, and 235nt of 3’ flanking intron (total amplicon size: 809 nucleotides) using 
Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/), an online tool for primer design 
61
.   To do 
this, BRCA2 exon 14 and 250 nt of flanking intron was inputted into Primer3 using hg19 
sequence build on the UCSC genome browser 
62
.   The SantaLucia salt adjusted melting 
temperature parameter, which refers to a publication by SantLucia et al. (1998) 
63
, which 
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accounts for the presence of divalent cations during primer melting temperature  
calculation, was used as recommended by Primer3 
64
.  Also, the recommended 
SantaLucia Table of Thermodynamic parameters was used during primer design, which 
incorporates primer duplex initiation parameters based on terminal G-C and A-T base 
pairs in the standard entropy calculation.  Further parameters include: a minimum 
forward and reverse primer melting temperature difference of 2°C, primer length between 
20-30nt (27nt optimal), and GC content between 20-80%.  A primer pair amplifying a 
809bp fragment (BRCA2:g.32,928,852-32,929,660) fitting all parameters was chosen.  
The DNA amplicon was then submitted as a “user sequence” to the ASSA server to 
ensure the information content changes observed when examining the variant in the 
genomic context was the same.   The 5’ end of forward primer was designed to include a 
BamHI restriction enzyme binding site, and the 5’ end of the reverse primer was designed 
to include an MluI binding site for subsequent digestion, and ligation into mini-gene 
plasmid.  Complementarity to BRCA2 begins at the first nucleotide after the restriction 
sites.  Primer sequences shown below were ordered from Integrated DNA Technologies 
(IDT): 
 
Forward: 5’ GACCGGATCCGTTTTGGAATGGCAACCATGGTGAATA 3’ 
(BamHI site) Tm=56.7°C, Length: 37nt 
 
Reverse: 5’ GACCACGCGTGTAACAGCAGTAATAGATTGTGTGTCT 3’ 
(MluI site) Tm=58.2°C, Length: 37nt 
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In addition to patient genomic DNA, HapMap (GM18859) genomic DNA homozygous 
for the reference allele at BRCA2:c.7319, as determined using the Coriell SNP Browser 
(Coriell Institute for Medical Research) was used to act as a WT control. First, patient 
and HapMap GM18859 genomic DNA (80ng) were PCR amplified using Platinum Pfx 
DNA polymerase (Invitrogen catalog#: 11708-013) according to the manufacturer’s 
instructions and primers shown above at an annealing temperature range of 47-58°C for 
27 cycles.  PCR products were spin-column purified (Qiagen catalog#: 28104) and gel 
visualized on a 1% agarose gel; a band was observed at expected size of 809 base pairs at 
an annealing temperature of 53°C.   
 
ii) Restriction enzyme digestion of PCR products and mini-gene plasmids.   PCR 
products were quantified using Nanodrop 2000 spectrophotometer (Thermo Scientific), 
and 333ng of patient and HapMap PCR products were double digested using: 25 units 
each of BamHI and MluI restriction enzymes (New England Biosciences catalog#: 
R0136S and R0198S respectively), 5μL NEBuffer 3 and 5μg Bovine Serum Albumin in a 
50μL reaction volume at 37°C for three hours.  Products were spin column purified 
according to manufacturer’s specifications (Qiagen catalog#: 28104).   
 
pcDNA-Dup and pCAS2 mini-gene plasmids were obtained from Dr. Mario Tosi at 
Institute National de la Santé et de la Recherche Médicale (INSERM) Unité 614 Rouen, 
France.  For ligation of PCR products into mini-gene plasmid, pCAS2 (4.18μg) was 
digested using 25 units each of BamHI and MluI restriction enzymes, 5μL NEBuffer 3 
and 5μg Bovine Serum Albumin in a 50μL reaction volume at 37°C for three hours.  
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After digestion, pCAS2 was treated with 5 units of Antarctic Phosphatase (New England 
Biosciences catalog#: M0289S) according to manufacturer’s instructions, to prevent 
vector self-ligation.   
 
iii) Ligation of digested PCR products into mini-gene plasmid. 0.023pmol of pCAS2 
was used as a starting point for ligation reactions of various insert:vector molar ratios.  To 
calculate the mass of 0.023pmol of pCAS2, the size of digested pCAS2 (7556bp) was 
multiplied by the average molar mass of one DNA base pair (~660 g/mol/bp), which 
results in 5.0x10
6
 g/mol of pCAS2.  Multiplying the molar mass of pCAS2 by 
0.025pmol, results in 115ng.   Using the same formula, the molar mass of PCR product 
insert was calculated to be 5.339x10
5
 g/mol. 
 
Digested patient and HapMap PCR products were ligated into digested, phosphatase-
treated pCAS2 at 0:1, 0.5:1, 1:1, 3:1 and 5:1 PCR-product:pCAS2 molar ratios, using 
0ng, 12.2ng, 12.2ng, 36.6ng and 55ng of PCR product respectively, and 115ng, 330ng, 
115ng, 115ng, and 101ng of pCAS2 vector respectively. Digested patient and HapMap 
DNA were combined with digested, phosphatase-treated pCAS2 in separate reactions, 
and were ligated using 400 units of T4 DNA ligase and 1/10 volume of T4 DNA ligase 
buffer.  Samples were then incubated at 16°C for 16.5 hours, followed by 15 minute 65°C 
enzyme heat inactivation.  Ligation products were visualized on a 1% agarose gel. 
 
iv) Recombinant mini-gene plasmid transformation into DH5-α Escherichia Coli 
cells.  Approximately 58ng of ligation products of all molar ratio conditions were 
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transformed into 200μL of competent DH5-α Escherichia Coli cells by first combining 
DNA and cells, and resting them on ice for 30 minutes.  Tubes were transferred to a 
circulating water bath at 42°C for 90 seconds, and placed back on ice for 2 minutes.  
Next, 800μL of Super Optimal Broth was added to each sample (2g tryptone, 0.5g yeast 
extract and 0.05g NaCl was added to 95mL of deionized water and mixed to dissolve.  
Next, 1mL of 250mM KCl was added, solution was brought up to 100mL using 
deionized water and autoclaved, when cooled, 0.5mL of 0.22μm filter sterilized 2M 
MgCl2 was added).  Samples were incubated at 37°C on a shaker at 225 cycles/minute for 
40 minutes.  After transformation, 10μL, 15μL, 100μL and 150μL of cells and media 
were plated onto separate ampicillin-containing Luria broth agar plates (1.25g tryptone, 
0.625g yeast extract, 1.25g NaCl, 1.875g agar, add deionized water to 125mL, boil, let 
cool, add 12.5mg ampicillin, mix and pour ~3mm thin layer into sterile 100x15mm petri 
dishes), and incubated overnight at 37°C.   
 
To confirm the success of transformation of insert-containing plasmid as well as 
determine the optimal ligation ratio condition, PCR amplification of mini-gene insert was 
performed the next day on four or five colonies from each ligation condition plate 
depending on colony density. Autoclaved toothpicks were used to gently touch individual 
colonies, which were then suspended into separate 0.2mL Eppendorf tubes containing 
5μL of nuclease free water.  To reduce the risk of inadvertently sampling multiple 
colonies, which would result in template heterogeneity, only isolated, easily accessible 
colonies were chosen from each plate.  The fraction of isolated colonies varied based on 
colony density.  The fraction of isolated colonies in the 10μL, 1:1 ligation ratio condition 
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corresponds to 4 of 12 colonies, whereas in the 100μL, 1:1 ligation ratio condition, only 1 
of 310 colonies was chosen.  Therefore, five colonies in total were examined from the 1:1 
ligation ratio condition, as well as five from the 3:1 ligation ratio condition, and four 
from each 0.5:1 and 5:1 based on sampling only isolated colonies.  Fifteen microliters of 
Taq Polymerase Master mix prepared according to manufacturer’s instructions 
(Invitrogen catalog#: 10342-053) containing primers specific to insert, shown previously, 
was added to each tube.  Tubes were incubated at 94°C for four minutes to lyse cells, 
which was followed by 27 cycles of amplification.  Amplification products were spin 
column purified (Qiagen catalog#: 28104) and run on a 1% agarose gel.  Two colonies 
from 0.5:1 ligation ratio plates showing amplification at the desired size of 809bp were 
transformed into DH5-α cells and grown in 25mL of Super Optimal Broth overnight at 
37°C on a shaker at 225 cycles/minute.  Plasmids were then purified using a PureYield 
Midi prep Kit (Promega, catalog # A2492) and sent to the London Regional Genomics 
Facility sequencing facility (London Regional Genomics Centre, London ON) using 
insert specific forward primer to confirm genotype of patient and HapMap DNA at the 
BRCA2:c.7319 locus.   
2.1.3 Preparation of mini-gene construct for investigation of 
putative splicing variant, BRCA1:c.548-16G>A  
 
The BRCA1:c.548-16G>A variant (rs80358171, no alternate allele population frequency 
data, listed in BIC as unknown clinical significance), is predicted to create a cryptic 
acceptor site (ΔRi = -2.8>5.4 bits) 14 nucleotides upstream of the exon 8 while decreasing 
the information content of the natural acceptor site (ΔRi = 0.5>0.2 bits).  Further 
explanation is provided in Chapter 3.1.  To examine this variant, a recombinant mini-
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gene construct was created using the same workflow described in the previous section.  
This variant was found in Mucaki et al. (2011) and is not part of the London Health 
Sciences Centre patient cohort.  Since patient DNA was unavailable, the BRCA1:c.548-
16G>A mutation was introduced using the primers used during PCR amplification.  
Therefore, two forward primers, one encoding the mutation of interest, and one encoding 
the WT nucleotide, were designed to amplify HapMap genomic DNA (GM18860) to 
create mutant and WT products respectively.   
 
i) PCR amplification of variant and WT  
For PCR amplification, primers were designed using Primer3 under the same parameters 
and constraints listed previously, to amplify exon 8 of BRCA1 as well as 44nt of 5’ 
flanking intron and 210nt of 3’ flanking intron (total amplicon size 300bp).  The 5’ end of 
forward primers were designed to include a BamHI recognition site, and the 3’ end of the 
reverse primer was designed to include an MluI recognition site for subsequent digestion, 
and ligation into digested pCAS2.  Complementarity to BRCA1 begins at first nucleotide 
downstream of restriction sites.  Primer sequences shown below were ordered from IDT: 
 
Mutant forward (mutant nucleotide in bold):  
5’ GACCGGATCCAAGAAAACTTTTATTGATTTATTTTTGAGGGGAAATT 3’ 
(BamHI) Tm=55.8°C, Length: 47nt 
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Wild-type forward (wild-type nucleotide in bold):  
5’ GACCGGATCCAAGAAAACTTTTATTGATTTATTTTTGGGGGGAAATT 3’ 
(BamHI) Tm=57.4°C, Length: 47nt 
 
Reverse:  
5’ GACCACGCGTGGTATGCTTAGTACCCGGATGATGA 3’ 
(MluI) Tm=57.7°C, Length: 35nt 
 
HapMap genomic DNA (100ng) was PCR amplified in two conditions, one using WT 
forward primer and the other using mutant forward primer.  Amplification was performed 
using Platinum Pfx DNA Polymerase (Invitrogen catalog#: 11708-013) according to the 
manufacturer’s instructions, with primer annealing temperatures ranging from 57-67°C, 
and in the presence of 5% v/v DMSO in the WT condition to prevent primer secondary 
structure.  Amplification products were spin column purified (Qiagen catalog#: 28104) 
and visualized on a 2.5% agarose gel, an amplicon was observed at the expected size of 
300bp at an annealing temperature of 61.1°C for the WT condition and 58.6°C for the 
mutant condition.   
 
ii) Restriction enzyme digestion of PCR products and mini-gene plasmids  
PCR products were quantified using a Nanodrop 2000 spectrophotometer, and 333ng of 
WT and mutant amplification products were double digested using: 25 units each of 
BamHI and MluI restriction enzymes, 5μL NEBuffer3, and 5μg Bovine Serum Albumin 
in a 50μL reaction volume at 37°C for three hours.   
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iii) Ligation of digested PCR products into mini-gene plasmid  
Digested PCR products were then ligated into digested, phosphatase-treated pCAS2 
vector using T4 DNA ligase in 0:1, 1:1, 1.5:1 and 3:1 insert:pCAS2 molar ratios, using 
0ng, 20.9ng, 31.35ng and 62.7ng of digested PCR products respectively, as well as 115ng 
of digested, phosphatase-treated pCAS2 in each condition. 
 
Digested PCR product insert and digested, phosphatase-treated pCAS2 were ligated using 
400units of T4 DNA ligase and 1/10 volume of T4 DNA ligase buffer according to 
manufacturer’s instructions (New England Biosciences catalog#: M0202S) at 16°C for 
16.5 hours, followed by 15 minute 65°C enzyme heat inactivation.  
 
iv) Recombinant mini-gene plasmid transformation into DH5-α Escherichia Coli 
cells  
Wild type and mutant recombinant vectors were transformed into competent DH5-α cells, 
plated onto ampicillin-containing Luria broth agar plates, and incubated overnight at 
37°C as described in the previous section.  To confirm the success of transformation of 
insert-containing plasmid as well as determine the optimal ligation ratio condition, PCR 
amplification of mini-gene insert was performed the next day on three colonies from each 
ligation condition plate, using the same autoclaved toothpick, lysis and PCR method 
described previously.  Amplification products were spin column purified (Qiagen 
catalog#: 28104) and run on a 2.5% agarose gel.  Colonies from (1:1 ligation ratio for 
WT, 1:1.5 ligation ratio for mutant) plates showing amplification at the desired size of 
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300 bp were transformed into DH5-α cells and grown in 25mL of Super Optimal Broth 
overnight at 37°C and 225 cycles/min.  Plasmids were then purified using a PureYield 
Midi Prep Kit (Promega, catalog#: A2492) and sent to the London Regional Genomics 
Facility for Sanger sequencing using standard T7Pro forward primer to confirm WT and 
mutant conditions had the proper genotype. 
2.1.4 Preparation of mini-gene construct for investigation of 
putative splicing variant, BRCA1:c.288C>T  
 
 
The BRCA1:c.288C>T variant is predicted to abolish ESE elements:  
SRp40 (ΔRi = 2.6>-2.9 bits) and SF2/ASF (ΔRi = 6.6>0.9 bits), both located in exon 5, 14 
nucleotides upstream of the natural donor site.   Abolishing splicing regulatory binding 
sites in close proximity to the natural donor site is predicted to lead to reduced donor site 
recognition by the spliceosome and lead to aberrant splicing.  A more detailed 
explanation of why this variant was chosen for splice site analysis is provided in Chapter 
3.1.  To investigate this variant, the variant and 17 nucleotides upstream and downstream 
was inputted into the ASSA server as a user defined sequence to confirm that information 
theory predictions are the same as when examining the variant from the genomic context.  
To examine the effects of BRCA1:c.288C>T on splicing, two complementary 55-mer 
DNA oligonucleotides encoding the putative mutated SRp40 and SF2/ASF site were 
designed, as well as a pair of oligonucleotides encoding the WT nucleotide. 
Oligonucleotides were designed to encode a EcoRI and BamHI restriction site for 
subsequent digestion and ligation into pcDNA-Dup mini-gene vector.  Undigested 
pcDNA-Dup not containing recombinant insert was used as a control for cassette exon 
exclusion in downstream transfection and RT-PCR experiments.  Oligonucleotide 
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sequences shown below were ordered from IDT, regions complementary to BRCA1 are 
shown below in brackets: 
 
Mutant Forward (mutation in bold): 
5’GACCGAATTC(TGTGCTTTTCAGCTTGATACAGGTTTGGAGTGTAA)GGATCC
GACC 3’ 
 (5’ EcoRI and 3’ BamHI) Tm=72.1°C, Length: 55nt 
 
Reverse complement:  
5’GGTCGGATCC(TTACACTCCAAACCTGTATCAAGCTGAAAAGCACA)GAATT
CGGTC 3’ 
Tm=72.1°C, Length: 55nt  
 
Wild-type Forward (WT nucleotide in bold): 
5’GACCGAATTC(TGTGCTTTTCAGCTTGACACAGGTTTGGAGTGTAA)GGATC
CGACC 3’ 
 (5’ EcoRI and 3’ BamHI) Tm=72.8°C, Length: 55nt 
 
Reverse complement:  
5’GGTCGGATCC(TTACACTCCAAACCTGTGTCAAGCTGAAAAGCACA)GAATT
CGGTC 3’ 
 Tm=72.8°C, Length 55nt 
 
40 
 
Next, WT and mutant forward and reverse strands (2μg each) were annealed separately in 
two tubes by first heating at 95°C for 6 minutes, and ramping down 1°C per minute until 
samples reached 26°C.  After annealing, 1μg of double-stranded product was digested 
using: EcoRI and BamHI restriction enzymes (New England Biosciences catalog #: 
R0101S and R0136S respectively), 1.5μL MgCl2, 5μL NEBuffer 3 and 5μg Bovine 
Serum Albumin in 50μL reaction volume at 37°C for three hours.  Next, 5μg of pcDNA-
Dup was sequentially digested with EcoRI and BamHI restriction enzymes and treated 
with Antarctic Phosphatase according to manufacturer’s instructions.  Digested insert and 
vector were then ligated using T4 DNA ligase as described previously in 0:1, 5:1 and 
10:1 insert:vector molar ratios.  Ligation products were then transformed into competent 
DH5-α cells and plated onto ampicillin containing plates as previously described.  
Colonies were then selected from each ligation condition using autoclaved toothpicks for 
heat lysis and PCR amplification of insert as described previously.   Amplification 
products were run out on a 4% gel and bands at the expected size of 97bp were observed.  
Colonies were then transformed into DH5-α cells and grown in 25mL of Super Optimal 
Broth overnight at 37°C.  Plasmids were then purified using a PureYield Midi prep Kit 
(Promega, catalog # A2492) and sent to the London Regional Genomics Facility for 
Sanger sequencing using standard T7Pro forward primer to ensure the insert was present.   
2.1.5 Transfection of recombinant mini-gene vectors in MDA-MB-
231 breast cancer cell line  
 
 
Different mRNA splice isoforms transcribed from the same gene exist in different tissue 
types 
65
.  Tissue-specific expression of RNA binding proteins involved in splicing 
promotes alternative splicing across tissues.  To mimic endogenous levels of proteins 
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involved in splicing in breast tissue, recombinant mini-gene vectors were transfected into 
breast cancer cell line MDA-MB-231.  This cell line has been used to transfect vectors 
derived from the same backbone using the same transfection reagent (FuGene6) in a 
previous study conducted by Morelli et al. (2003) 
66
.  One 1mL vial of MDA-MB-231 
cells was removed from a liquid nitrogen tank and immediately placed in 37°C water 
bath.  When thawed, vial was wiped with 70% ethanol and placed in cell culture hood 
sterilized with 10% bleach and 70% ethanol.  Cells were placed in 15mL Falcon tube, 
and 10mL of pre-warmed Dulbecco’s Modified Eagle Medium (Sigma-Aldrich product#: 
RNBC3976), containing 10% Fetal Bovine Serum (Fisher product#: SH3007003), 1% 
penicillin and 1% streptomycin (Invitrogen product#: 15140122) was added and mixed.  
Cells were pelleted at 1000xg for 9 minutes.  Supernatant was discarded, and cells were 
resuspended in 7mL of complete media.  Cells were then transferred to T25 flask 
(BDBiosciences catalog#: 353108) and placed in an incubator at 37°C, 5% CO2.  When 
cells reached 80% confluency, cells were trypsinized, plated onto two T75 flasks 
(BDBiosciences catalog#: 353136) and returned to the incubator. When cells reached 
80% confluency, they were trypsinized again and split into four T75 flasks and returned 
to incubator.  When flasks reached 80% confluency, cells were trypsinized and counted 
using a hemacytometer.  Next, eight six-well plates (VWR product#: 82050-846) were 
seeded with 3x10
5 
cells/well in complete media to total 3mL of cells and media per well 
as recommended by Fugene6 transfection reagent protocol (Promega, catalog#: E2691).  
Cells were returned to incubator and retrieved the following day for transfection when 
they reached ~80% confluency.   
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Cells were transfected with eight plasmids, one plasmid per plate, these include: empty 
pcDNA-Dup (containing no insert), empty pCAS2 (containing no insert), pCAS2 mini-
gene containing BRCA1:c.548-16G WT and BRCA1:c.548-16G>A mutant, pCAS2 mini-
gene containing BRCA2:c.7319A WT and BRCA2:c.7319A>G mutant, and pcDNA-Dup 
mini-gene containing BRCA1:c.288C WT and BRCA1:c.288C>T mutant.  A total of 3μg 
of plasmid DNA was transfected in each well using FuGene6 transfection reagent.  This 
was calculated by multiplying the amount of DNA suggested for one well of a 96 well 
plate (0.1μg) by the relative growth area multiplication factor for a 6-well plate (30X) 
provided as described in the FuGene6 transfection reagent protocol.   
 
Plasmids were transfected in three ratios of FuGene6 transfection reagent to plasmid 
DNA: 1.5:1, 3:1 and 6:1 (μL:μg).  First, transfection reagent was incubated for 5 minutes 
at room temperature with a volume of pre-warmed serum free media necessary to bring 
the final volume up to the recommended 150 uL/well.  
 
Next, 3μg of plasmid DNA was added to transfection reagent/media mixture.  Tubes were 
mixed and incubated for 15 minutes at room temperature.  Next, 150μL of mixture was 
added to each well corresponding to plasmid and reagent:plasmid ratio, with one plasmid 
per plate, and two wells per ratio condition.  Plates were returned to incubator.  To select 
for transfected cells harboring plasmid, the backbone of which encodes a neomycin 
resistance gene, twenty-four hours later, 1.5mg of filter sterilized 200μg/μL G418 (VWR, 
product#: E859-1G) was added to each well of each plate, to a final concentration of 
500ug/mL, as used by Morelli et al. 
66
.  After adding G418, cells were returned to 
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incubator.  Forty-eight hours later, 25μg of 5ug/μL filter-sterilized puromycin (Sigma 
catalog#: P8833-10MG) was added to three of six wells of each plate (final concentration 
per well: 8.33μg), one for each reagent:plasmid ratio, as recommended by Tournier et al. 
(2008) 
47
 to inhibit nonsense mediated decay and thus allow for extraction of RNA 
transcripts encoding premature stop codons.  Next, 5.5 hours after puromycin was added, 
cells were washed with 1XPBS and trypsinized.  Cells for each condition were pelleted 
and divided into two tubes, one for RNA extraction, one for DNA extraction.   
 
Total RNA was extracted using Trizol LS (Invitrogen catalog#: 10296-028) according to 
the manufacturer’s instructions.  RNA was resuspended in 48μL of nuclease free water 
and 2μL of RNaseIN (Promega catalog#: N2611), and split into two 25μL aliquots.  
Samples were ethanol precipitated twice to remove residual Trizol reagent contamination, 
and achieve 260/280 and 260/230 absorbance ratios of between 1.9-2.1 and 1.7-2.3 
respectively, as determined on Nanodrop spectrophotometer.   
 
Plasmid DNA was extracted from cells using Trizol reagent, and was subsequently 
purified using a Qiagen spin mini-prep kit according to manufacturers instructions, as has 
been performed by Ziegler et al. in 2004 to extract low-molecular weight circular DNA 
from mammalian cells 
67
.   
2.1.6 Reverse transcription of extracted mRNA 
 
RNA was isolated from both WT and mutant plasmid conditions corresponding to: 
BRCA2:c.7319A>G, BRCA1:c.548-16G>A and BRCA1:c.288C>T variants at 1.5:1 and 
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3:1 transfection ratios.  Next, 10μL of DNase I solution (stock DNase I solution made by 
mixing: 10μL of 100mM MgCl2, 0.5μL of 1.0 mg/mL DNase I, 0.5μL of RNaseIN, and 
39μL of TE buffer) was added to 10μL of RNA (1.1μg total) and mixed.  Solution was 
incubated at 37°C for 15 minutes before adding 1μL of 0.05M EDTA.  Solution was 
mixed and heat inactivated at 65°C for 20 minutes.  Solutions were placed on ice. 
 
RNA was reverse transcribed (RT) using Superscript II Reverse Transcriptase 
(Invitrogen: 18064-022) using 250pg of random hexamers according to the manufactures 
instructions.  To validate success of RNA extraction and reverse transcription, an aliquot 
of the RT reaction (1μL) was PCR amplified using Taq DNA Polymerase according to 
manufacturer’s instructions in addition to HapMap GM19200 RNA to act as a positive 
control.  cDNA derived from endogenously expressed VSP39 mRNA, was PCR 
amplified using primers designed using Primer3 using parameters described in 2.1.2 to 
amplify a 103bp cDNA fragment at an annealing temperature of 59°C.  VSP39 was 
chosen as a positive control for RNA extraction and RT-PCR because previous 
microarray expression data revealed that splicing index and intensity levels of this exon 
of VSP39 had the lowest variability across 176 HapMap samples examined.  Low levels 
of expression and splicing variability across samples supports use of VSP39 as a stable 
gene to act as a positive control for RNA extraction and RT-PCR. Primer sequences are 
shown below: 
 
Forward: 5’ CTCAGTTCCATCAAAACTCGGTTT 3’ Tm= 55.6°C, Length: 24nt 
Reverse: 5’ GAAGCCAAGACACACAGTGCTG 3’ Tm= 58.7°C, Length: 22nt 
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Next, cDNA derived from endogenously expressed BRCA2 mRNA was PCR amplified at 
52°C using primers designed using Primer3 using parameters described in 2.1.2 to bind 
the 3’ end of exon 11 (forward primer, chr13:g.32,152,254-32,915,276), and across the 
exon11-exon12 junction (reverse primer), yielding an expected amplicon size of 96bp.  
This PCR was conducted as an additional control to ensure that the RNA extraction and 
reverse transcription steps were successful, and that mRNA splicing of endogenously 
expressed genes is efficient in MDA-MB-231 cell line.  Primer sequences are shown 
below: 
 
Forward: 5’ TACATGTCCCGAAAATGAGGAAA 3’ Tm=54.3°C, Length: 23nt 
Reverse: 5’ TTGATTGAGGGTTCTCCCACTAAG 3’ Tm=56.3°C, Length: 24nt 
 
BRCA1:c.548-16G and BRCA2:c.7319A WT cDNA was PCR amplified for 30 cycles 
using primers specific to the first and last exon of pCAS2 mini-gene (Table 1, primer 
identifier numbers 5 and 6) as recommended by INSERM at an annealing temperature of 
57°C.   PCR amplification was performed with and without 1M betaine.  An additional 
PCR reaction was performed at a lower annealing temperature of 55°C. Products were 
electrophoresed on a 2% agarose gel.   
 
cDNA corresponding to pcDNA-Dup mini-gene vectors was PCR amplified using Taq 
polymerase according to manufacturer’s instructions and primers designed to bind the T7 
Promoter (forward) and exon 2 of pcDNA-Dup mini-gene (reverse) and an annealing 
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temperature of 57°C as recommended by INSERM, for 30 cycles.  The sequence of the 
forward primer is presented in Table 1 (identifier 1) and the sequence of the reverse 
primer is presented below.  PCR products were electrophoresed and resolved on a 2.5% 
agarose gel. 
 
Reverse primer: 5’ GGACTCAAAGAACCTCTGGG 3’ Tm= 60.5°C, Length: 20nt 
 
As a control experiment to determine the effectiveness of DNase I digestion, varying 
concentrations of stock pcDNA-Dup plasmid DNA were digested with DNase I using the 
same procedure listed previously except using plasmid template amounts of 440ng, 
220ng, 110ng and 20ng.  DNase I digested plasmid was then PCR amplified for 35 cycles 
using primers specific to pcDNA-Dup mini-gene listed above.  pcDNA-Dup plasmid, 
DNase I treated pcDNA-Dup plasmid and mini-gene PCR amplified DNase I treated 
plasmid was electrophoresed on a 1.5% agarose gel.  DNase I digested plasmid was then 
PCR amplified a second time for 25 cycles using the same mini-gene specific primers. 
 
Next, primers were designed to span exon-exon junctions, using Primer3 under standard 
parameters described in 2.1.2, to selectively amplify cDNA corresponding to spliced 
RNA.  Each cDNA product was PCR amplified in two conditions, one using primers 
designed to amplify WT mini-gene cDNA, the other using primers designed to amplify 
mutant mini-gene cDNA.  Mini-gene cDNA (1μL of RT reaction) was PCR amplified 
using Taq polymerase according to manufacturer’s instructions under a range of 
annealing temperatures (52-56°C) for pcDNA-Dup cDNA (includes: empty pcDNA-Dup, 
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BRCA1:c.288C WT, BRCA1:c.288C>T Mutant), and pCAS2 cDNA (includes: empty 
pCAS2, BRCA1:c.548-16G WT, BRCA1:c.548-16G>A mutant,  BRCA2:c.7319A WT, 
and BRCA2:c.7319A>G Mutant).  PCR products were resolved on 2% agarose gel using 
electrophoresis.  Primers used during PCR are shown in Table 1. 
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Table 1.  Primers for mini-gene cDNA PCR amplification following reverse transcription 
Plasmid condition Primer sequence (5’>3’) Binding site Amplicon size 
(bp) 
Tm 
(°C) 
Length (nt) Identifier 
pcDNA-Dup no 
cassette exon 
Forward 
TAATACGACTCACTATAGGG Upstream of 
pcDNA-Dup 
mini-gene 
209 54.3 20 1 
pcDNA-Dup no 
cassette exon 
Reverse 
AGCCTGCCCAGGGCCTCA Across first 
and second 
exon of 
pcDNA-Dup 
mini-gene 
209 62.9 18 2 
pcDNA-Dup 
cassette exon 
Forward 
GGCAGGCTGAATTCTGTGCTT Across first 
and cassette 
exon of 
pcDNA-Dup 
mini-gene 
63 61.2 21 3 
pcDNA-Dup 
cassette exon 
Reverse 
AGCCTGCCGGATCCTTACAC Across 
cassette and 
third exon of 
mini-gene 
63 62.5 20 4 
pCAS2 
BRCA1:c.548-16 
no middle exon 
Forward 
TGACGTCGCCGCCCATCAC First exon in 
pCAS2 mini-
gene 
280 57 19 5 
pCAS2 
BRCA1:c.548-16 
no middle exon 
Reverse 
ATTGGTTGTTGAGTTGGTTGTC Last exon in 
pCAS2 mini-
gene 
280 57 22 6 
pCAS2 
BRCA1:c.548-16 
middle exon 
Forward 
GGCTGGGGATCTGATTCTTC Across first 
and middle 
exon of 
pCAS2 mini-
220 60.5 20 7 
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gene 
pCAS2 
BRCA1:c.548-16 
middle exon 
Reverse 
GACAACCAACTCAACAACCAAT Last exon in 
pCAS2 mini-
gene 
220 57 22 8 
pCAS2 
BRCA2:c.7319 no 
middle exon 
Forward 
TGACGTCGCCGCCCATCAC First exon of 
pCAS2 mini-
gene 
280 (no middle 
exon), 667 
(truncated 
middle exon) 
57 19 9 
pCAS2 
BRCA2:c.7319 no 
middle exon 
Reverse 
ATTGGTTGTTGAGTTGGTTGTC Last exon of 
pCAS2 mini-
gene 
280 (no middle 
exon), 667 
(truncated 
middle exon) 
57 22 10 
pCAS2 
BRCA2:c.7319 
middle exon 
Forward 
TGCTGGCTGGGCACAACTAA First exon 
and middle 
exon of 
pCAS2 mini-
gene 
610 60.5 20 11 
pCAS2 
BRCA2:c.7319 
middle exon 
Reverse 
ATTGGTTGTTGAGTTGGTTGTC Last exon of 
pCAS2 mini-
gene 
610 57 22 12 
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Wild-type and mutant BRCA2:c.7319A>G were PCR amplified using primers specific to 
WT and mutant mini-gene transcript displayed in Table 1 (primer identifiers 11 and 12 
for WT mini-gene transcript and 9 and 10 for mutant mini-gene transcript).  cDNA was 
PCR amplified using Taq polymerase according to manufacturer’s instructions according 
to the thermocycler program: 95°C (3 min), 10 cycles of: 94°C (45 seconds), 67°C (20 
seconds) ramping down -1°C per cycle, 72°C (25 seconds);  this was followed by 30 
cycles of: 94°C (45 seconds), 57°C (20 seconds), 72°C (25 seconds), and a final 
elongation step at 72°C (1 minute).  cDNA was also amplified using final annealing 
temperatures of 53°C, 54°C for WT primers and 55°C and 56°C for mutant primers.  All 
products were electrophoresed on a 2% agarose gel. 
 
pcDNA-Dup derived plasmid cDNA corresponding to BRCA1:c.288C WT, 
BRCA1:c.288C>T mutant and empty pcDNA-Dup were PCR amplified at an annealing 
temperature of 56°C under the following conditions using Taq polymerase: 95°C (3 min), 
10 cycles of: 94°C (45 seconds), 66°C (20 seconds) ramping down -1°C per cycle, 72°C 
(25 seconds);  this was followed by 30 cycles of: 94°C (45 seconds), 56°C (20 seconds), 
72°C (25 seconds), and a final elongation step at 72°C (1 minute).   Products were 
electrophoresed on a 2% agarose gel. 
 
cDNA corresponding to WT BRCA2:c.7319A and BRCA1:c.548-16G and 3:1 
transfection ratio conditions were PCR amplified using Taq Polymerase according to 
manufacturer’s instructions using primers designed to amplify: pCAS2 mini-gene 
containing middle exon and no middle exon (primer identifiers: 7 and 8; 5 and 6 
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respectively, at an annealing temperature of 52°C) for BRCA1:c.548-16G>A, and pCAS2 
mini-gene containing middle exon and no/aberrant middle exon (primer identifiers: 11 
and 12; 9 and 10 respectively, at an annealing temperature of 52°C).  PCR products were 
electrophoresed on a 2% agarose gel. 
2.2 Estimation of number of breast cancer families with BRCA1 
and BRCA2 variants using a Power Analysis  
 
 
Breast cancer patients at LHSC are categorized into a series of groups defined by the 
incidence and age-of-onset of breast, ovarian and/or other HBOC in first, second or third 
degree relatives.  The Molecular Diagnostics Laboratory at LHSC has provided the 
number of patients in each group.  The estimated proportion of families with BRCA1 and 
BRCA2 mutations was determined through linkage frequency published by Ford et al. 
(1998) 
28
.  In the Ford et al. (1998) study, genetic information was obtained for 237 
families with breast and/or ovarian cancer from the Breast Cancer Linkage Consortium 
(BCLC), which is a consortium that harbors genetic information for over 700 families 
with hereditary breast cancer and aims to evaluate the cancer risks conferred by BRCA1 
and BRCA2.  Genetic markers on 17q21 flanking BRCA1, including D17S579 (Hall et al. 
1992) and D17S250 (centromeric to BRCA1) were used to determine linkage frequency 
of BRCA1 to breast and/or ovarian cancer.  Genetic markers flanking BRCA2, D13S260 
(centromeric to BRCA2) and D13S267 were used to determine linkage of breast and/or 
ovarian cancer to BRCA2.  Additional linkage and mutation studies were used to estimate 
the frequency of BRCA1 and BRCA2 mutations in patients with bilateral breast cancer 
68
 
and breast-ovarian 
69 
cancer.  The total number of deleterious BRCA1 and BRCA2 
mutations detected in each group of breast cancer patients was obtained from the 
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molecular diagnostics lab.  Dividing this by the total number of patients in each group 
gives the fraction of patients with detected deleterious variants.  Subtracting the fraction 
of detected BRCA1 and BRCA2 variants by the fraction of BRCA1 and BRCA2 variants 
predicted by linkage and mutation analyses, gives the estimated fraction of undetected 
variants by patient group.  Multiplying the estimated fraction of undetected variants by 
the total number of patients in each group gives the predicted number of patients with 
undetected variants in BRCA1 and BRCA2.  An online power analysis calculator (Soper 
D.S. 2010; http://www.danielsoper.com/statcalc3/calc.aspx?id=1) was used to determine 
the minimal sample size in each group needed to detect a pathogenic variant in BRCA1 
and BRCA2, using the fraction of undetected variants as effect size, for a statistical power 
of 0.8 and probability cutoff of <0.05.   
2.3 Capture Array design and synthesis and library preparation 
methodology 
 
Patient genomic DNA (gDNA) was purified by the Molecular Diagnostics Laboratory at 
LHSC from patient blood samples using MagNA Pure Compact Nucleic Acid Isolation 
kit I (Roche, catalog#: 03 730 964 001).  Genomic DNA from twenty-one breast cancer 
patients with a family history of breast cancer was obtained from the Molecular 
Diagnostics Laboratory at LHSC.  Patient gDNA was prepared for sequencing on the 
Illumina Genome Analyzer IIe using a genomic DNA solution capture procedure 
described by Gnirke et al. (2009) 
42
.  In the protocol outlined by Gnirke et al., 
oligonucleotide probes are designed to hybridize to regions of interest on sheared 
genomic DNA, and are synthesized on a microarray chip.  Probes are then cleaved from 
the array, and transcribed in vitro to biotinylated RNA, using biotinylated uracil as 
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described in section 2.4 (see Figure 2).  These probes are then hybridized in solution to 
sheared, adapter ligated DNA and subsequently captured on streptavidin-coated magnetic 
beads.  After enrichment, samples are PCR amplified and paired-end sequenced on the 
Illumina GAIIe.  Several modifications of the protocol outlined by Gnirke et al. (2009) 
were introduced in this study, including: 1) 24,000 custom designed oligonucleotide 
probes targeting 36-70mer single-copy and divergent repetitive sequences (both forward 
and reverse strands) were synthesized on two separate microarrays (versus 10,000 
200mer probe sequences from Agilent Technologies), 2) cleaved probes were PCR 
amplified using a forward primer encoding an SP6 promoter for downstream in vitro 
transcription (versus T7 Promoter), 3) enzymatic library DNA preparation in the presence 
of Agencourt magnetic beads in final sequencing run, 3) 36bp (first two sequencing runs) 
and 50bp (final sequencing run) paired-end sequencing runs were conducted on the 
Illumina Genome Analyzer II on enriched patient DNA (versus 76bp paired-end 
sequencing). 
2.4 Probe design and synthesis 
 
 
Twenty-four thousand 36-70mer oligonucleotide probes were designed for independent  
hybridizations to the forward and reverse strands of seven breast cancer-associated gene 
sequences. These included exonic, intronic, and adjacent intergenic regions separately for 
targeted enrichment and downstream sequencing.  Separating hybridizations into two 
reactions, one with forward strand specific probes, the other with reverse strand specific 
probes, ensures that complementary forward and reverse strand probes do not anneal to 
each other during incubation.  These seven genes include: ATM, BRCA1, BRCA2, CDH1, 
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CHEK2, PALB2 and TP53, and were chosen based on hereditary breast cancer linkage 
studies described in Chapter 1.4 
29,32,34–36
.   Only these seven genes with published 
causative alleles involved in breast cancer etiology were chosen for probe design in this 
study.  
 
Within these seven genes, probes were designed to hybridize to intronic, exonic and 5’ 
and 3’ untranslated regions (UTR), in addition to 10kb upstream and downstream of each 
gene.  Only ab initio identified, single-copy sequences were chosen for probe design, as 
described by Dorman et al. (2013) 
70
, as well as regions within repetitive elements 
lacking non-divergent repeats (<30% divergence).  We used ab initio single copy 
sequences for probe design in order to increase the coverage of unique regions for capture 
and sequencing, including regions containing divergent repetitive elements, which under 
the stringent conditions used, should hybridize only to these targets.  
 
Eligible 36-70mer oligonucleotide probes within ab initio single-copy and divergent 
repeat regions, were chosen using microarray design software PICKY 2.2.  Settings used 
for probe design include: 30-70% GC content, Tm=65°C+2°C, a 20nt maximum overlap 
between probes, and a maximum of five probes per 100nt interval, all other settings were 
set to default.  Probes were designed for both forward and reverse strands to be 
synthesized on two separate microarrays to prevent annealing to each other. Using the 
program, “Amalgamated-Post-Picky-Program”, sequences were analyzed for overlap and 
cross-hybridization to other regions of genome (hg19) and transcriptome using BLAT 
62
.  
Any gaps in probe coverage within exons greater than five nucleotides were filled 
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manually by designing unique probes to span these regions with similar predicted melting 
temperature.   To examine the effects of RNA probe secondary structure, a program 
called “UNAFOLD” was used to calculate the Gibbs free energy of probes at 
hybridization temperature.  Those with values less than -10 kcal/mol were redesigned to 
minimize secondary structures.     
 
Probes were then synthesized on two cleavable 12K CustomArray chips, one 
corresponding to probes on the forward strand, the other to probes on the reverse strand, 
using a Combimatrix CustomArray Synthesizer.  To PCR amplify probes after cleavage 
from the array, primer-binding sequences taken from Gnirke et al. 2009 were added to 
the 5’ and 3’ ends of 36-70mer probe sequences, as shown below, where N36-70 
corresponds to the target region probe: 
 
5’ ATCGCACCAGCGTGT-N36-70-CACTGCGGCTCCTCA 3’ 
 
This Excel spreadsheet was copied and pasted into Notepad and saved on a computer 
containing a program called ProbeWeaver.  This file was then opened in ProbeWeaver 
and saved as a chip design file.   
 
To synthesize arrays, a pre-capping protocol designed to expose the chip to capping 
reagents CapA (Sigma, product#: L040250-1) and CapB (Sigma, product#: L050250-01) 
15 minutes prior to synthesis was performed to reduce the number of initiation sites and 
oligonucleotide density, reducing the load on the membrane.  Next, the chip design file 
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was loaded, and reagent volumes were checked, the acetonitrile keg was full and the 
waste container was empty.  A fresh solution of reagents needed for electrochemical 
oligonucleotide synthesis on the CustomArray microarray synthesizer, termed E-chem 
solution, was prepared prior to synthesis by adding 700mL of acetonitrile (Sigma 
product#: 271004-20L-P2) and 200mL of methanol (Fisher product#: AC14280) to a 
large jar containing magnetic stir bar, followed by 1.08g of benzoquinone (Fluka 
Analytical, product#: 12309-100G), 110.11g of hydroquinone (Sigma, product#: 
H17902-2KG), 15.16g of tetra-ethylammonium p-toluenesulfonate (Sigma, product#: 
134473-500G), and 0.59mL of 2,6-lutidine (Sigma, product#: 336106-100ML).  Solution 
was mixed for ten minutes and connected to Combimatrix CustomArray Synthesizer.  
Two 12K cleavable CustomArray chips, one for forward strand specific probe synthesis, 
one for reverse strand specific probe synthesis, were loaded into two slots on the 
Combimatrix CustomArray Synthesizer.  Next, the microarray chip was tested for 
connections and the chip design protocol was run.   
 
After synthesis, oligonucleotide probes were cleaved from the arrays using 14.5M 
ammonium hydroxide (Carolina, item# 844010) to cleave sulfonyl-amidite bond linking 
oligonucleotide to array, leaving 3’ phosphate on oligonucleotides.  First, the newly 
synthesized arrays were placed in CombiMatrix CustomArray Stripping Clamp manifolds 
and sealed.  Next, 500μL of 14.5M ammonium hydroxide was added to each stripping 
clamp.  The arrays were then incubated in the manifold at 65˚C for four hours.  The 
liquid was removed from the manifolds and placed in two 1.5mL Eppendorf tubes, which 
were then placed into a SpeedVac RC110A for one hour at 65˚C.  The resulting pellet 
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was resuspended in 100μL of 1X TE buffer and purified using a MicroSpin column 
(Roche catalog#: 11814419001).   Forward and reverse oligonucleotide probes (1μL of 
final reaction) were then PCR amplified separately using Platinum Pfx DNA Polymerase 
(Invitrogen, catalog#: 11708-013) and primers complimentary to primer binding sites on 
probes 
42
 according to the program: 95°C (4 minutes), 25 cycles of: 98° (20 seconds), 
55°C (15 seconds), 72°C (15 seconds), and a final elongation step of 72°C (5 minutes), 
followed by 4°C (hold).  Nested PCR was then performed on resultant product (3μL of 
25μL previous reaction) using a forward primer encoding a 5’ SP6 promoter site, 
retrieved from SP6 KapaBiosystems kit, using Kapa HiFi DNA polymerase ReadyMix 
(KapaBiosystems Code: KK2101) for 25 cycles under the same program described 
above.  PCR product was purified on MinElute column and eluted in 30μL of nuclease 
free water.   
 
Next, SP6 promoter-containing probes (1μg from column purified DNA brought up to 
12μL using nuclease free water) were transcribed in vitro using MAXIscript SP6 in vitro 
transcription kit according to manufacturer’s instructions (Ambion cat. no. AM1308), 
while incorporating biotin-labeled UTP (Roche catalog#: 11388908910) in a 1:4 
biotinylated:non-biotinylated ratio.  Nascent RNA mixture was incubated with TURBO 
DNase I (1μL) provided in MAXIscript SP6 in vitro transcription kit at 37°C for 15 
minutes.  DNase I digestion was stopped by adding 0.5M EDTA (1μL).  Products were 
ethanol precipitated and resuspended in 30μL of nuclease free water before adding 2μL 
of RNaseIN (Promega catalog#: N2611).  RNA bait pool was stored at -80°C. 
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2.5 Library preparation methodology  
 
Six patient gDNA samples and one HapMap gDNA sample (GM19145) were prepared 
for the first sequencing run on the Illumina Genome Analyzer IIe. Genomic DNA 
samples (5μg) were suspended in 100μL of nuclease free water and sonicated using 
Covaris Ultrasonicator Model S220 at the London Regional Genomics Facility under the 
following settings: Time: 120 seconds, Duty Cycle: 20%, Intensity: 4, Cycles per burst: 
200. 
 
After sonication, samples were removed from the instrument and purified on a QiaQuick 
spin column (Qiagen, product#: 28104), eluting in 50μL of nuclease free water.  Samples 
were imaged on a 3% agarose gel to ensure shearing, which is indicated by a smear of 
DNA fragments.  Using Kapa Library Preparation kit (KapaBiosystems KK8201), 
sheared DNA was end repaired according to manufacturer’s instructions to produce blunt 
ends.  Samples were immediately purified using MinElute PCR purification kit (Qiagen 
product#: 28004) and eluted in 31μL of provided elution buffer.  Next, addition of a 3’ 
adenine nucleotide (“A-tailing”) was performed on end-repaired DNA using Kapa 
Library Preparation kit; samples were purified using MinElute PCR purification kit.   
 
Single-stranded Illumina Paired End (PE) Adapters, as well as their complements, were 
ordered from IDT.  Sequences are shown below: 
i) PE Adapter 1: 5' GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 3’ 
ii) PE Adapter 1 complement: 
5’ CTCGGCATTCCTGCTGAACCGCTCTTCCGATC 3’ 
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iii) PE Adapter 2: 5’ ACACTCTTTCCCTACACGACGCTCTTCCGATCT 3’ 
iv) PE Adapter 2 complement: 
5’ AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT 3’ 
 
Adapter sequences obtained from IDT were resuspended in nuclease free water to 
200μM.  Complementary single-stranded adapters were annealed by mixing equal 
volumes of 200μM of each strand, i) and ii), and iii) and iv) separately, and incubated on 
a thermocycler at 98°C while ramping down 0.1°C per second, until samples reach 4°C.  
Products were diluted to 30μM using nuclease free water.  Nascent 30uM double-
stranded Illumina PE adapters (5μL) were ligated to sheared, A-tailed patient DNA using 
Kapa Library Preparation kit, and incubating at 20°C for 15 minutes.  Samples were 
purified using a MinElute PCR purification kit.  Following adapter ligation, samples were 
resolved on 2% low electroendoosmosis (EEO) agarose gel, and DNA within 200-300bp 
was gel extracted using Qiagen Gel Extraction kit.  Extracted DNA was PCR amplified 
under the following parameters using Kapa Library Preparation kit: 98°C (45 seconds), 
followed by 15 cycles of 98°C (15 seconds), 65°C (30 seconds), 72°C (30 seconds), and 
finally one 72°C (60 seconds) step and holding at 4°C. 
 
Adapter ligated, sheared patient and GM19145 samples were then hybridized to RNA 
probes using the using a series of solutions made with the following reagents as described 
in CustomArray targeted sequencing kit version 2.2: Neutralization buffer (1M Tris-HCl, 
pH 7.5), Wash buffer 1 (2mL 1X Saline Sodium Citrate buffer, 4mL 0.1% Sodium 
Dodecyl Sulfate, 34mL nuclease free water), Wash buffer 2 (0.1X Saline Sodium Citrate 
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buffer, 4mL 0.1% Sodium Dodecyl Sulfate (SDS), 34mL nuclease free water), Bead 
Binding buffer (2.3376g of 1M NaCl, 400μL of 10mM Tris HCl, 80μL of 1μM EDTA 
and nuclease free water up to 40mL), Denhardt’s solution, and 20X Saline-sodium 
phosphate EDTA (SSPE) buffer.   
 
Adapter-ligated, sheared patient and HapMap DNA solution (500ng in varying volumes 
depending on patient sample) was concentrated to 3.4μL using a SpeedVac RC110A.  
Next, Library Mix was prepared by adding 2.4μL of 1μg/μL human COT-1 DNA, 2.5μL 
of 1μg/μL salmon sperm DNA and 0.6μL of 25μM Paired-end PCR primers (each) to 
3.4μL of patient and HapMap DNA in a thermocycler tube.  A Hybridization buffer mix 
was prepared by combining: 25μL of 20X SSPE buffer, 1μL of 0.5M EDTA, 10μL of 
50X Denhardt’s solution, and 13μL of 1% SDS. Oligo Bait Library mix was prepared by 
mixing 5μL of 100ng/μL of biotinylated RNA bait and 1μL of RNaseIN (Promega 
catalog#: N2611).  Seven times the volume of solutions was made above to accommodate 
7 samples.  To hybridize patient and HapMap DNA to biotinylated RNA bait, Library 
DNA mix was incubated at 95°C for 5 minutes to denature DNA.  Next, samples were 
cooled to 65°C.  When thermocycler reached 65°C, Hybridization buffer mix was added 
to fresh 0.2mL Eppendorf tubes placed in thermocycler.  Library and Hybridization 
buffer mixes were incubated at 65°C for 3 minutes, when Oligo Bait mix was added to 
clean 0.2mL Eppendorf tubes and placed in thermocycler.  After 2 minutes of incubation, 
Library mix and Hybridization buffer mix were added to tubes containing Oligo Bait mix, 
and solution was mixed by pipetting.  Solution was hybridized at 65°C for 66 hours.   
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To capture DNA hybridized to biotinylated RNA bait, 100μL of MyOne Streptavidin 
coated magnetic Dynabeads T1 (Invitrogen #656-01) was placed into each of six 1.5mL 
Eppendorf tubes, which were washed with Bead binding buffer three times, and then 
suspended in 400μL of Bead binding buffer.  This solution was partitioned equally into 
six additional clean 1.5mL tubes, for a total volume of 200μL of beads and Bead binding 
buffer in each tube.  The Hybridization/DNA mix was added to tubes containing beads, 
and tubes were placed onto a nutator at room temperature for 30 minutes to promote 
binding of DNA:RNA hybrid to magnetic beads.  Beads were then pelleted on magnetic 
separator (Ambion product#: AM10026) and supernatant was removed and replaced with 
1mL of Wash buffer 1.  Beads were briefly vortexed and incubated for 15 minutes at 
room temperature.  Beads were separated again, and supernatant was removed and 
replaced with 1mL of Wash buffer 2 that was pre-warmed to 65°C.  Beads were 
incubated for 10 minutes and briefly vortexed.  Washing with Wash buffer 2 was 
repeated two more times.  Beads were then mixed with 100μL of Elution Buffer (0.1M 
NaOH) and incubated for 10 minutes at room temperature.  Beads were separated and 
supernatant containing DNA was transferred to six tubes containing 140μL of 
Neutralization buffer.  Samples were purified using MinElute PCR purification kit, and 
eluted in supplied Elution Buffer.   
 
Purified, captured DNA was then PCR amplified using Kapa HiFi DNA Polymerase 
(KapaBiosystems Code: KK2101) for 27 cycles.  Quantitative PCR was then performed 
on amplified DNA to determine volume needed for concentration of 10nM required for 
Illumina GAIIe sequencer.  This was performed using Kapa qPCR kit according to the 
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manufacturers instructions (KapaBiosystems Code: KK4600).  Next, 5μL of 10mM 
captured DNA samples were sequenced on the Illumina GAIIe through 36bp, paired-end 
reads in addition to Illumina PhiX control v3.  The PhiX control v3 is an adapter ligated 
DNA library generated from PhiX-174 bacteriophage genome that is used to assess 
cluster generation, sequencing and alignment (Illumina Technical Note: Sequencing) 
71
.    
 
Seven patient genomic DNA samples were prepared for a second sequencing run 
according to the same protocol with a few alterations.  One alteration includes the post-
capture PCR amplification step, which was reduced from 27 to 24 cycles to reduce PCR 
amplification bias, and maximize the number of unique DNA fragments to improve 
sequencing coverage and accurate variant detection.  Also, magnetic bead separation was 
performed using six-channel DynaMag Spin Magnet (Invitrogen product#: 12320D), thus 
reducing sample preparation time.  After library preparation, samples were sequenced on 
the Illumina GAIIe through 36 base pair, paired-end reads in addition to PhiX control. 
 
Finally, eight patient genomic DNA samples were prepared for the final sequencing run 
according to the same protocol performed during the second library preparation with one 
major alteration.  All pre-hybridization enzymatic reactions, including: end-repair, A-
tailing, and adapter ligation, were prepared in the presence of Agencourt AMPure XP 
beads (Beckman Coulter, item#: A63880).  Agencourt AMPure beads are carboxyl-
coated paramagnetic beads that remove DNA from solution using a mixture of 20% 
polyethyleneglycol (PEG) and 2.5M NaCl, which forces DNA molecules to bind to 
carboxyl group on beads, which can then be separated on a magnet 
72
.  Supernatant can 
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then be removed and replaced with the reagents of a subsequent enzymatic reaction after 
a brief 70% ethanol wash.  Use of Agencourt AMPure beads eliminates sample loss 
arising from gel extraction, MinElute spin-column purification and sample transfer, 
resulting in fewer PCR amplification cycles needed to achieve sufficient DNA quantities 
for sequencing, thus reducing PCR amplification bias, generating more unique reads and 
higher sequence coverage.   In addition to using AMPure beads during the final library 
preparation, samples were paired-end sequenced using two 50 base reads, instead of 36 as 
used in the previous two sequencing runs.  Finally, Illumina GAII Sequencing Control 
Software (SCS) and Real Time Analysis software was upgraded to version 2.10 (from 
2.9) and 1.13 respectively.  This update resulted in improved image analysis, producing 
more high-quality data, which impacts overall base coverage and quality scores. 
2.6 Sequencing data analysis  
 
 
All raw base intensity data generated during sequencing was converted to DNA sequence 
and aligned to the human genome using CASAVA v.1.7 (first two sequencing runs) and 
v.1.8 (final sequencing run) software (Illumina).  In version 1.7, from Intensity files 
produced during sequencing, base calls are generated using a program called “Bustard”.  
From base calls, paired-end reads are aligned to the hg19 reference genome using a 
program called “Gerald”, which is a collection of Perl scripts and C++ executables that 
use an alignment algorithm called, Efficient large-scale alignment of nucleotide databases 
version 2 (ELANDv2), to perform multiseed and gapped alignment of paired-end reads to 
the reference sequence in parallel (Illumina CASAVA1.7 user guide, pg 43).  Where a 
“seed” is defined as a substring of bases within a read that is extracted and aligned to the 
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reference sequence.  A gapped alignment is when an alignment program maps a read 
containing a gap within its sequence compared to the reference sequence to the reference 
sequence and can allow the detection of indels.  Aligned sequences are converted to 
Sequence Alignment Map (SAM) file format in CASAVA v.1.7 using a Perl script called 
“export2sam”, which takes read 1 and read 2 export files generated by Gerald as input 
and converts them to a text-based sequence alignment map (SAM) format.  SAM files 
were then used to generate variant calls.  The final sequencing run of eight patients used 
an updated version of CASAVA, version 1.8.  In this version, several program directories 
were changed, in addition to the final file output, which is in Binary Alignment Map 
(BAM) format, as opposed to SAM format, which is a compressed, indexed binary 
version of SAM file.  In the final sequencing run, sequences were aligned only to 
chromosomes containing the genes of interest on the hg19 version of the human genome, 
as opposed to the entire genome, to reduce computation time.   
 
SAM and BAM files generated by CASAVA were then further processed on the Shared 
Hierarchical Academic Research Computing Network (SHARCNET) for variant calling 
using “Picard” (http://picard.sourceforge.net), a program containing a set of Java-based 
command-line utilities that process BAM files in preparation for variant calling by 
removing PCR duplicates, identifying paired-end mate pairs and realigning reads around 
indels, “Samtools” (http://samtools.sourceforge.net/) 73, a program containing utilities 
designed to index, sort and merge SAM files, and the “Genome Analysis Toolkit” 
(GATK) 
74
, a software package developed at the Broad institute for genotyping and 
sequencing variant detection.  All SAM files generated from CASAVA v.1.7 were 
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converted to BAM files using the samtools “view” command in SHARCNET.  From 
BAM files, the MarkDuplicates.jar file from Picard (http://picard.sourceforge.net/) was 
used to flag PCR duplicates.  All flagged duplicates were disregarded during downstream 
variant calling.  After duplicate marking, read groups specifying the sequencing date, 
lane and platform were added to each BAM file using the AddOrReplaceReadGroups.jar 
file from Picard.  BAM files were then indexed using samtools index command.  Indexed 
BAM files were then realigned around indels using the RealignerTargetCreator.jar and 
FixMatePair.jar files from Picard.  Finally variants and indels were called using the 
UnifiedGenotyper tool in GATK with the GATK recommended standard call confidence 
value of 30 (a minimum phred base quality score to call variants), and files were exported 
in vcfv4.1 format.  After all variants were called, only variants within target regions were 
examined further.  Reference and alternate allele coverage values were extracted from the 
column 10 of the final output (corresponding to the AD value in vcf format, 
“DepthPerAlleleBySample”).   
 
To determine the location of the variant (i.e. intronic, exonic, upstream of gene, 
downstream of gene, or 5’ and 3’ UTR), the final variant output file was formatted for 
input into an online database called SNPNexus 
75
, which a SNP Annotation tool that 
determines the location of a genetic variant (i.e. exon, intron, UTR etc. in hg19 genome 
nomenclature), amino acid changes (when applicable) and any SNP’s corresponding to 
that variant (dbSNP and HapMap).  Variants can also be examined for putative effects on 
protein structure and miRNA binding sites using SNPNexus which accesses publically 
available mutation prediction tools such as PolyPhen 
76
, PolyPhen 2 
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(http://genetics.bwh.harvard.edu/pph2/index.shtml), and SIFT 
77
, which predicts the 
effects of amino acid substitution on protein structure and function, and miRBase 
78
 and 
TargetScanHuman
79
, which predict putative miRNA binding sites by examining the 
presence of conserved 7-8mer sites in human UTRs matching miRNA seed region.  After 
inputting variants and selecting individual prediction tools, such as miRBase, the output 
file will contain predicted effects of variants on miRNA binding. All variants within 
exonic regions were catalogued along with corresponding amino acid changes, and 
whether variant corresponds to a previously described SNP.   
 
Reference and alternate allele coverage values were used to filter out likely false positive 
variant calls as a result of sequencing artifacts.  Although variants with a low fraction of 
reads calling the variant allele may be true heterozygous variants, all variants need to fall 
within a confidence interval for reliable variant detection.  To do this, an online binomial 
probability calculator was used to determine the minimum number of reads calling the 
alternate allele to be considered a true variant within a 95% confidence interval for 
variants of varying total coverage (http://stattrek.com/online-calculator/binomial.aspx).  
 
First, all variants within each gene were examined in silico for putative effects on 
splicing using the, “Shannon Human Splicing Pipeline” 80, a high-throughput software 
that analyzes the effects of variants detected in large sequencing experiments on 
canonical splice sites using information theory, followed by the Automated Splice Site 
and Exon Definition Analysis (ASSEDA) server (http://ossify.sg.csd.uwo.ca), which 
predicts the effects of variants on splice site information content and the resulting mRNA 
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isoform using information theory and the exon definition model.   The ASSEDA server 
predicts aberrant mRNA isoforms as a result of splice site inactivation or cryptic splice 
site activation through changes in the total amount of information content (Ri TOTAL) of 
each splice site contributing to exon recognition by the spliceosome.  Exons with the 
greatest total information content have the highest abundance within mRNA isoforms.  
When predicting pairs of acceptor and donor splice sites defining an exon, in addition to 
the sum of information content of the constitutive splice sites, a logarithmic gap surprisal 
function is used in the calculation of the total information content of spliced exon.  The 
gap surprisal function is based on the observation by Robberson et al. (1990) 
81
 that long 
exons, although present in the genome (n=1115 known exons >1000bp), are recognized 
by the spliceosome more inefficiently than shorter exons 
82
.  Studies using transcriptome-
wide distribution of exon lengths have determined the most common internal exon length 
(96bp), which is used to normalize the gap surprisal penalty when calculating total exon 
information content 
82
.  Putative exons with lengths deviating from the normalized exon 
length are penalized, and the total information content of the putative exon goes down.  
The exons with greater Ri TOTAL values are predicted to have a more predominant presence 
in final mRNA transcripts.   
 
Variants were formatted to accommodate the Shannon pipeline’s specifications, which 
includes four tab-delineated columns in a text file: chromosome (i.e. chr17), identifier, 
hg19 variant coordinate, and nucleotide variant (i.e. C/T).  A file containing all single 
nucleotide variants was uploaded to the Shannon pipeline plug-in on the CLC-Bio 
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Genomics Workbench to analyze effects of variants on natural and cryptic donor and 
acceptor splice sites using the hg19 human genome as a reference.   
 
The resultant information was then further prioritized for effects on splicing based on the 
following criteria: 1) variant results in >1 bit information content decrease in a natural 
splice site (corresponds to a two-fold decrease in spliceosome binding affinity) 
45
.  In 
vitro mRNA splicing assays, and gene expression analyses have found that a two-fold 
change in binding affinity is a threshold for detecting splicing and gene expression 
changes 
46,54
. 2) Information content of affected cryptic splice site must be greater than 
nearest proximal natural site, and must reside within 300nt of the natural site.  This is 
based on the observation by Robberson et al. (1990) that stable exons will be formed only 
if 3’ and 5’ splice sites are found in the correct orientation and are usually within 300nt of 
each other 
81
. Therefore, although some variants >300bp from the natural splice site can 
produce cryptic sites with greater information content than the natural splice site, the 
change in exon length produced if the site were chosen would result in a total information 
content less than that of the natural exon due to the gap surprisal function.  
 
Variants fitting these criteria were organized into three categories: putative leaky splicing 
mutations, inactivating mutations and cryptic mutations.  Prioritized variants in hg19 
nomenclature were examined on the ASSEDA server to predict mutant mRNA isoforms. 
 
Variants in all probe-designed regions were examined for effects on sixty transcription 
factor binding sites (TFBS) using a program called, “Mutation Analysis”, which 
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calculates changes in information content of TFBS as a result of variants, and generates 
an output file containing all changes TFBS changes in information content as a result of 
mutations.  Transcription factor ChIP-seq data was downloaded from the Encyclopedia of 
DNA Elements (ENCODE) consortium, and filtered with ENCODE H3K27 acetylation 
and DNase I hypersensitivity tracks to select for only DNA regions accessible to 
transcription factors for binding.  Transcription factors identified through ENCODE 
ChIP-seq studies that map to regions within the promoters of the seven genes in this 
study, as determined by turning on ENCODE transcription factor binding track on the 
UCSC Genome Browser were included in the analysis.  Epigenetically-filtered ChIP-seq 
data was aligned using a program called Bipad 
83
, which performs multiple local 
alignments by entropy minimization to predict sequence elements within unaligned 
sequence data.  Common sequences recognized by each individual transcription factor 
within a set of defined lowest entropy sequences identified using Bipad are used to build 
transcription factor binding site models.  Sequence models are constrained by specifying 
that each sequence contain either one or zero binding sites per submitted sequence 
(ZOOPS).  The probe-design regions are filtered using ENCODE H3K27 acetylation and 
DNase I HS in HMEC cell line (human mammary epithelial tissue) and resultant regions 
are scanned for putative transcription factor binding sites generated from aligned 
sequence models.  Changes in transcription factor binding site information content due to 
sequence variants, is calculated using Bipad-generated position weight matrices in a 
program called “Mutation Analysis”.   
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The following criteria is used to prioritize variants for effects on transcription factor 
binding sites from the Mutation Analysis output data: 1) variants must occur within 10kb 
of transcription start site, because in addition to the core promoter located within 200bp 
of the transcription start site (TSS), DNA sequence clusters that insulate or enhance 
transcriptional activation can be located up to 100kb upstream of the TSS in humans, 
such as the transcriptional enhancer motif regulating Igf2 expression in humans and mice 
84,85
.  Examining transcription factor ChIP-seq data from ENCODE on the UCSC genome 
browser reveals clusters of transcription factor binding sites located several kilobases 
upstream of breast cancer associated genes examined in this study, as well as within 
coding sequences such as CDH1.  Therefore probing regions up to 10kb outside of the 
TSS is necessary for detection of potential functionally relevant TFBS altering mutations 
associated with breast cancer etiology.  2) Variants must occur in accessible chromatin 
regions in mammary tissue as determined through HMEC (mammary epithelial cell line) 
epigenetic data from ENCODE.  3) Variants must affect TFBS’s with information 
content greater than one standard deviation (SD) below the mean information content of 
each particular TFBS.  The mean TFBS information content filter prioritizes variants 
affecting only putative TFBS that bind transcription factors with moderate to high affinity 
(with respect to other TFBS of the same transcription factor).  TFBS with information 
content less than 1 SD below the mean information content are less likely to be 
functionally relevant due to weak interaction with transcription factor proteins.  4) 
Finally, variants must result in a >1 bit information content decrease of TFBS, which 
corresponds to a 2-fold protein binding affinity change.  Although it has been shown that 
the loss of transcription factor binding as a result of a mutation is proportional to the 
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impact of its match with the TFBS position weight matrix 
86
, variants that significantly 
alter a TFBS position weight matrix score (i.e. information content change), can still 
result in TF binding, as in the case of human CFTF binding 
67
, which is thought to be due 
to heterologous protein-protein interactions.  Therefore although a mutation can 
significantly alter TFBS information content, it may still be active in vivo through 
protein-protein interactions with other TF’s 67,87, thus limiting prioritization to mutations 
resulting in >1 bit decrease of TFBS information content may detect some functionally 
relevant mutations, but not all due to regulation mediated by protein-protein interactions 
with other TF’s.  Filtered variants were further prioritized based on degree of information 
content change, proximity to transcription start site and the information content of the 
TFBS prior to mutation.   
 
Variants found within the 5’ and 3’ UTRs of the seven genes were examined in silico for 
potential effects on mRNA structure using an online tool called “SNPfold” 88.  SNPfold 
compares the base-pairing probability of each base in a mutated RNA sequence to the 
wild-type RNA sequence in a matrix called the partition function.  Each base in the 
sequence is then ranked according to the degree to which it likely affects the RNA 
structure based on base-pairing probabilities. Then, sorted p-values are calculated for the 
set of input variants by dividing the base rank by the total number of bases in the 
sequence.  Complete 5’ and 3’ UTR sequences of each gene containing one or more 
variants identified in breast cancer patients were inputted SNPfold including all variants 
encoded within their sequences.  Variants with p-values <0.05 (in a few instances <0.10) 
were prioritized as variants most likely to affect the stability of the RNA structure of the 
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sequenced gene.  Variants meeting p-value cut-offs were submitted to Alain Laederach to 
confirm that UTR’s harboring variants should be validated by SHAPE analysis.   
 
Variants predicted to alter RNA structure were then assessed for effects on RNA binding 
protein-binding sites (RBPBS) using RBPBS position weight matrices obtained from the 
RNA binding protein database (RBPDB) 
89
.   Position weight matrices were entered into 
the Shannon pipeline, and differences in information content of RBPBS as a result of 
putative RNA structure-altering UTR variants were generated.  Variants predicted to 
result in information content changes of >2 bits in RBPBS’s with initial information 
contents of 3 bits or greater were prioritized.  The number of RNA-binding protein 
binding sites used in developing position weight matrices and models are relatively small, 
resulting in a higher standard deviation in information content.  Therefore a higher 
threshold of information content change in RBPBS with high average information 
content was used as a prioritization criteria to increase variant prioritization stringency 
and reduce false positives.   
 
Variants in 3’ UTRs were inputted into SNPNexus while selecting for predicted effects 
on miRNA binding through TargetScanHuman 
79
 and miRBase databases 
78
. Since 
SNPNexus does not report the location of miRNA binding sites and only if a variant is 
predicted to affect a binding site, the location of miRNA binding sites was determined 
through the miRBase Sequence Database by turning on snoRNA/miRNA tracks on the 
UCSC genome browser 
78
 and examining the 3’ UTR of genes harboring variants.  
Searching TargetHumanScan for predicted miRNA binding sites in these genes was also 
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performed by inputting the gene into TargetHumanScan and mapping predicting sites to 
the UCSC Genome Browser.  To support SNPNexus results, variant location was 
compared to putative miRNA binding sites in 3’ UTRs of genes harboring variant.  
 
Primers were designed to amplify regions containing prioritized variants using Primer3 
for amplification of patient gDNA for variant Sanger sequencing validation.  Prioritized 
variants from patients were amplified using Platinum Pfx DNA Polymerase and Kapa 
HiFi DNA Polymerase according to manufacturer’s instructions.  Products were purified 
using Qiagen MinElute spin columns, and sent to the London Regional Genomics 
Facility for Sanger sequencing.   
 
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
Chapter 3 Results 
3.1 Results of LHSC patient BRCA1 and BRCA2 variant 
nomenclature change and prioritization on splicing 
 
 
After all patient BRCA1 and BRCA2 variants identified by the Molecular Diagnostics 
Laboratory at LHSC were converted to HGVS cDNA nomenclature, a single file 
describing all variants was created.  A total of 158 novel variants are described (see Table 
3), with 89 variants in BRCA2 and 69 variants in BRCA1.  A breakdown of variant 
location, as well as amino acid alterations is summarized in Table 2.   
 
Table 2. Summary of BRCA1 and BRCA2 variants in LHSC patient cohort 
Gene No. 
variants 
in exon 
No. 
variants 
in 
intron 
No. 
variants 
in UTR 
No. 
variants 
causing 
missense 
changes 
No. 
truncating 
variants 
No. 
synonymous 
variants 
No. 
indels 
BRCA1 45 24 0 30 1 11 5 
BRCA2 75 13 1 46 2 24 4 
 
After examining 158 variants in the BIC database, it was found that 107 are listed as of 
unknown clinical significance or are not reported, 40 are listed as of no clinical 
significance, and 11 are listed as clinically significant. All variants were converted to 
hg15 reference genome coordinates and analyzed with the ASSA server to examine 
putative effects on splicing.  A total of 30 of 158 variants are predicted to result in splice 
site inactivation, 38 variants are predicted to strengthen cryptic splice sites, and 7, 
variants are predicted to weaken constitutive splice sites (resulting in leaky splicing).  A 
literature search of all variants expressed in HGVS (cDNA and hg19 reference genome) 
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and BIC genomic nomenclatures as defined in Chapter 1.2, was performed using: Google 
Scholar
TM
, PubMed, Web of Science Database (Thomson Reuters), Quertle
TM
 and 
Google
TM
. A table detailing all variants detected by routine sequencing converted to 
HGVS nomenclature for submission to the ENIGMA consortium is displayed in Table 3. 
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Table 3.  BRCA1 and BRCA2 variants detected by routine sequencing at the 
molecular diagnostics lab. 
Gene Variant (HGVS) Amino acid Number of patients 
BRCA1 c.42C>T p.Val14Val 1 
BRCA1 c.75C>T p.Pro25Pro 2 
BRCA1 c.80+77A>G   1 
BRCA1 c.81-11delT   1 
BRCA1 c.81-65G>C   1 
BRCA1 c.81-6T>C   3 
BRCA1 c.135-1G>T*   3 
BRCA1 c.140G>A p.Cys47Tyr 3 
BRCA1 c.181T>G* p.Cys61Gly 21 
BRCA1 c.212+3A>G   5 
BRCA1 c.213-11T>G*   2 
BRCA1 c.288C>T p.Asp96Asp 1 
BRCA1 c.301+7G>A   1 
BRCA1 c.441+36_49del   1 
BRCA1 c.441+36CTT>TTC   2 
BRCA1 c.442-34T>C   2 
BRCA1 c.455T>C p.Leu152Pro 3 
BRCA1 c.547+8T>G   1 
BRCA1 c.548-57delT   114 
BRCA1 c.591C>T p.Cys197Cys 3 
BRCA1 c.594-24A>C   4 
BRCA1 c.736T>G p.Leu246Val 1 
BRCA1 c.802A>G p.Asn268Asp 1 
BRCA1 c.981A>G p.Thr327Thr 2 
BRCA1 c.1067A>G p.Gln356Arg 148 
BRCA1 c.1308T>C p.Pro336Pro 1 
BRCA1 c.1487G>A p.Arg496His 4 
BRCA1 c.2050C>T p.Pro684Ser 2 
BRCA1 c.2077G>A p.Asp693Asn 335 
BRCA1 c.2082C>T p.Ser694Ser 889 
BRCA1 c.2311T>C p.Leu771Leu 23 
BRCA1 c.2315T>C p.Val772Ala 1 
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BRCA1 c.2412G>C p.Gln804His 2 
BRCA1 c.2477C>A p.Thr826Lys 1 
BRCA1 c.2521C>T p.Arg841Trp 8 
BRCA1 c.2596C>T p.Arg866Cys 1 
BRCA1 c.2612C>T p.Pro871Leu 1115 
BRCA1 c.3113A>G p.Glu1038Gly 548 
BRCA1 c.3119G>A p.Ser1040Asn 31 
BRCA1 c.3296C>T p.Pro1099Leu 4 
BRCA1 c.3302G>A p.Ser1101Asn 1 
BRCA1 c.3418A>G p.Ser1140Gly 3 
BRCA1 c.3454G>A p.Asp1152Asn 1 
BRCA1 c.3548A>G p.Lys1183Arg 525 
BRCA1 c.4039A>G p.Arg1347Gly 18 
BRCA1 c.4132G>A p.Val1378Ile 1 
BRCA1 c.4308T>C p.Ser1436Ser 555 
BRCA1 c.4327C>T* p.Arg1443X 2 
BRCA1 c.4357+17A>G   1 
BRCA1 c.4357+6T>C   2 
BRCA1 c.4362A>G p.Val1454Val 2 
BRCA1 c.4484+61G>T   1 
BRCA1 c.4535G>T p.Ser1512Ile 12 
BRCA1 c.4600G>A p.Val1534Met 1 
BRCA1 c.4654T>C p.Tyr1552His 1 
BRCA1 c.4750G>T* p.Ala1584Ser 1 
BRCA1 c.4812A>G p.Gln1604Gln 1 
BRCA1 c.4816A>G p.Lys1606Glu 1 
BRCA1 c.4837A>G p.Ser1613Gly 596 
BRCA1 c.4956G>A p.Met1652Ile 25 
BRCA1 c.4986+6T>G*   4 
BRCA1 c.4987-92A>G   22 
BRCA1 c.5074+3A>G*   4 
BRCA1 c.5075-53 C>T   1 
BRCA1 c.5083del19*   1 
BRCA1 c.5152+66G>A   1 
BRCA1 c.5277+48_5277+59Du   1 
BRCA1 c.5333-36del510*   1 
BRCA1 c.5406A>C p.Thr1802Thr 1 
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BRCA2 c.-26G>A   10 
BRCA2 c.3G>A* p.Met1Ile 6 
BRCA2 c.67+62T>G   2 
BRCA2 c.68-7T>A   3 
BRCA2 c.125A>G p.Tyr42Cys 9 
BRCA2 c.198A>G p.Gln66Gln 2 
BRCA2 c.223G>C p.Ala75Pro 3 
BRCA2 c.241T>A p.Phe81Ile 2 
BRCA2 c.387T>C p.Asp129Asp 1 
BRCA2 c.426-2A>G*   4 
BRCA2 c.475+1G>T*   2 
BRCA2 c.506A>G p.Lys169Arg 2 
BRCA2 c.865A>C p.Asn289His 106 
BRCA2 c.865A>G p.Asn289Asp 1 
BRCA2 c.978C>A p.Ser326Arg 4 
BRCA2 c.1151C>T p.Ser384Phe 3 
BRCA2 c.1365A>G p.Ser455Ser 77 
BRCA2 c.1395A>C p.Val465Val 1 
BRCA2 c.1514T>C p.Ile505Thr 1 
BRCA2 c.1599T>C p.Thr533Thr 4 
BRCA2 c.1698C>G p.Thr566Thr 2 
BRCA2 c.1786G>C p.Asp596His 3 
BRCA2 c.1792A>G p.Thr598Ala 5 
BRCA2 c.1909+12delT   10 
BRCA2 c.1938C>T p.Ser646Ser 3 
BRCA2 c.1964C>G p.Pro655Arg 2 
BRCA2 c.2229T>C p.His743His 76 
BRCA2 c.2803G>A p.Asp935Asn 5 
BRCA2 c.2883G>A p.Gln961Gln 9 
BRCA2 c.2971A>G p.Asn991Asp 75 
BRCA2 c.3218A>G p.Gln1073Arg 1 
BRCA2 c.3264T>C p.Pro1088Pro 2 
BRCA2 c.3396A>G p.Lys1132Lys 516 
BRCA2 c.3762G>T p.Glu1254Asp 1 
BRCA2 c.3807T>C p.Val1269Val 392 
BRCA2 c.4008_4009insCATC* p.Asp1337IlefsX2 1 
BRCA2 c.4046T>C p.Ile1349Thr 1 
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BRCA2 c.4068G>A p.Leu1356Leu 12 
BRCA2 c.4258G>T p.Asp1420Tyr 30 
BRCA2 c.4308T>C p.Ile1436Ile 4 
BRCA2 c.4319A>G p.Lys1440Arg 5 
BRCA2 c.4530C>T p.Pro1510Pro 3 
BRCA2 c.4563A>G p.Leu1521Leu 33 
BRCA2 c.4585G>A p.Gly1529Arg 1 
BRCA2 c.4656T>C p.Gly1552Gly 1 
BRCA2 c.4672A>T p.Ser1558Cys 2 
BRCA2 c.4686A>G p.Gln1562Gln 1 
BRCA2 c.5199C>T p.Ser1733Ser 18 
BRCA2 c.5312G>A p.Gly1771Asp 1 
BRCA2 c.5418A>G p.Glu1806Glu 1 
BRCA2 c.5455C>T p.Pro1819Ser 1 
BRCA2 c.5569G>T* p.Glu1857X 1 
BRCA2 c.5744C>T p.Thr1915Met 149 
BRCA2 c.5901G>A p.Lys1967Lys 2 
BRCA2 c.6100C>T p.Arg2034Cys 36 
BRCA2 c.6317T>C p.Leu2106Pro 2 
BRCA2 c.6322C>T p.Arg2108Cys 1 
BRCA2 c.6323G>A p.Arg2108His 6 
BRCA2 c.6757C>G p.Leu2253Val 1 
BRCA2 c.6842-68T>C   1 
BRCA2 c.6938-78A>T   1 
BRCA2 c.7007G>A* p.Arg2336His 6 
BRCA2 c.7008-62A>G   3 
BRCA2 c.7017G>C p.Lys2339Asn 1 
BRCA2 c.7242A>G p.Ser2414Ser 419 
BRCA2 c.7319A>G p.His2440Arg 1 
BRCA2 c.7435G>T p.Asp2479Tyr 8 
BRCA2 c.7469T>C p.Ile2490Thr 2 
BRCA2 c.7544C>T p.Thr2515Ile 4 
BRCA2 c.7806-14T>C   9 
BRCA2 c.7992T>A p.Ile2664Ile 4 
BRCA2 c.8149G>T p.Ala2717Ser 2 
BRCA2 c.8182G>A p.Val2728Ile 7 
BRCA2 c.8567A>C p.Glu2856Ala 6 
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BRCA2 c.8573A>G p.Gln2858Arg 1 
BRCA2 c.8755-66T>C   1 
BRCA2 c.8795A>C p.His2932Pro 2 
BRCA2 c.8904delC* p.Val2969CysfsX7 1 
BRCA2 c.8918G>A p.Arg2973His 3 
BRCA2 c.8953+98T>C   1 
BRCA2 c.9088A>C p.Thr3030Pro 1 
BRCA2 c.9257-16T>C   7 
BRCA2 c.9292T>C p.Tyr3098His 1 
BRCA2 c.9501+3A>T*   1 
BRCA2 c.9730G>A p.Val3244Ile 2 
BRCA2 c.9976A>T p.Lys3326X 77 
BRCA2 c.10095delCinsGAATTATATCT p.Ser3366AsnfsX4 2 
BRCA2 c.10110G>A p.Arg3370Arg 4 
BRCA2 c.10234A>G p.Ile3412Val 10 
* Variants previously determined to be clinically significant, and not submitted to 
ENIGMA consortium 
 
Putative splicing variants were prioritized for transfection analyses based on the 
following criteria: 1) the amount of information content change in the affected canonical 
or regulatory splice site (ΔRi), 2) the proximity of the affected regulatory splice site to the 
natural canonical splice site if applicable.  A study conducted by Lastella et al. (2004) 
examined 16 mutations in putative SF2/ASF motifs in exon 12 of hMLH1 predicted using 
the ESEfinder.  After conducting a mini-gene transfection study to examine the effects of 
variants in putative SF2/ASF sites, Lastella et al. (2004) determined that only 3 of 16 
lead to aberrant splicing, all three of which affected only SF2/ASF sites located within 40 
nucleotides of the acceptor and donor site 
90
.  As SR proteins binding ESE elements have 
been shown to facilitate spliceosome assembly at canonical splice sites through SR 
domain-mediated protein-protein interactions with the spliceosome components, the 
findings published by Lastella et al. (2004) should not be surprising 
15
.  Therefore 
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proximity to the canonical splice site is a criterion that was included when examining 
variants in putative ESE elements.  3) The number of canonical and regulatory splice 
sites affected by the mutation, and 4) the presence and proximity of a cryptic site of 
greater information content than an affected natural site.  Based on these criteria, two 
mutations, BRCA1:c.288C>T and BRCA2:c.7319A>G, shown in Table 4 were selected 
for further analysis, both of which may affect regulatory splice sites in close proximity to 
canonical splice sites.  Further explanation of the reasons why these variants were 
prioritized, as well as the putative mRNA splicing effects of these variants is described in 
the following paragraph. 
 
 
 Table 4.  Prioritized putative splicing variants in LHSC patient cohort 
Mutation Location Splice site(s) 
effect  
Ri initial 
(bits) 
Ri final (bits) 
BRCA1:c.288C>T 12 nucleotides 
upstream of 
natural donor 
site 
Abolished 
SRp40 and 
SF2/ASF 
2.6 and 6.6 -2.9 and 0.9 
BRCA2:c.7319A>G 117 
nucleotides 
upstream of 
natural donor 
site 
Creation of 
SRp40 
0.7 4.6 
 
The BRCA1:c.288C>T variant is located 12bp upstream of the natural donor site in exon 
5 of BRCA1 (see Figure 5).  The variant is predicted to abolish putative exonic splicing 
enhancer SRp40 (Ri = 2.6>-2.9 bits) and SF2/ASF (Ri = 6.6>0.9 bits) binding sites, both 
located 14 nucleotides upstream of the natural donor site.  As described in Chapter 1.3, 
SRp40 and SF2/ASF proteins facilitate 5’ and 3’ splice site recognition.  Therefore 
abolishing splicing regulatory binding sites in close proximity to the natural donor site is 
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predicted to lead to reduced donor site recognition by the spliceosome, and result in exon 
5 skipping, as no cryptic donor sites of greater information content than the natural donor 
site are found within 200 nucleotides of the natural donor.  Exon 5 skipping would reduce 
the mRNA transcript by 84 nucleotides, and result in a frameshift mutation.  The Human 
Splicing Finder version 2.4.1 
55
 predicts an abolished SRp40 site and reduced SF2/ASF 
site as a result of this mutation.  However, the ESEfinder version 3.0 predicts an SRp40 
site at the position of the mutation, but does not predict an SF2/ASF site.   
 
The BRCA2:c.7319A>G variant is located 117 nucleotides upstream of the natural donor 
site of exon 14 and is predicted to result in the creation of a cryptic SRp40 site (Ri = 
0.7>4.6 bits) located 120 nucleotides upstream of the natural donor site of exon 14 (hg19 
genomic coordinate, chr13:g.32,929,306; see Figure 5).  Examining the variant region on 
the ASSA server uncovered a cryptic donor site (Ri=2.3 bits) located 18 nucleotides 
downstream of the strengthened cryptic SRp40 site (hg19 genomic coordinate, 
chr13:g.32,929,324).  No ESE elements of greater information content are found within 
40 nucleotides of the natural donor site (Ri=2.4 bits).  Therefore this variant creates a 
putative cryptic SRp40 ESE site in close proximity to a cryptic donor site of comparable 
information content to the natural donor site with no nearby ESE elements of information 
content greater than or equal to the cryptic SRp40 site produced by the variant.  If the 
cryptic donor site is chosen, exon 14 could be truncated from 427 nucleotides to 326 
nucleotides, and thus result in a frameshift.  The Human Splicing Finder predicts creation 
of a cryptic SF2/ASF site four nucleotides upstream of the variant (final score=76.70), 
but does not predict the creation of a cryptic SRp40 site.     
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The BRCA1:c.548-16G>A variant described by Mucaki et al. (2011) 
46
 from the BIC 
database deposited by Myriad Genetics Inc. is located 16 nucleotides upstream of exon 8 
in BRCA1 (see Figure 5).  ASSA server analysis predicted natural acceptor splice site 
weakening (Ri=0.5>0.2 bits), and the creation of a cryptic acceptor site 14 nucleotides 
upstream of the first nucleotide in exon 8 (Ri =-2.8>5.4 bits).  If the cryptic acceptor site 
is activated, it is predicted to increase the length of exon 8 from 46 to 60 nucleotides and 
result in a frameshift mutation.  These results are consistent with results obtained from 
the Human Splicing Finder, which predicts the creation of a strong cryptic acceptor site 
(initial score=54.62, final weight score=83.57) that if used would increase exon length by 
14 nucleotides.  A schematic of the effects and location of prioritized variants on 
canonical and regulatory splice site information content is shown in Figure 5. 
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Figure 5.  Schematic of effects and location of prioritized variants on canonical and 
regulatory splice site information content.  Variants are marked by a long red, vertical 
line.  In the case of the BRCA2:c.7319A>G variant, cryptic donor site location is marked 
by a green line below D'.  SRp40 sites are marked in orange (vertical line most proximal 
to variant in both cases), and SF2/ASF sites are marked in yellow (vertical line distal to 
variant in both cases).   
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In addition to the variants prioritized for ex vivo transfection analysis, putative leaky 
splicing variants were also identified using the ASSA server, and are displayed in Table 
5.  Variant rsID, alternate allele population frequency as well as clinical significance 
(BIC) is also reported in the table.  A total of 15 patients harbor the putative leaky 
splicing variants.  Pedigree information was obtained from LHSC to examine patient 
family history of HBOC.  The average number of 1
st
, 2
nd
 and 3
rd
 degree relatives with 
HBOC for patients with each putative splicing variant is displayed in Table 5.   
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Table 5.  Breast cancer family history of patients with putative leaky splicing variants LHSC 
Gene Variant 
(HGVS) 
Ri 
initial 
(bits) 
Ri 
final 
(bits) 
ΔRi Type BIC 
clinically 
significant 
(yes/no/ 
unknown)  
rsID 
(dbSNP) 
Alternate 
allele 
population 
frequency 
(%) 
No. 
patients 
with 
variant 
Average 
no. 1
st
 
degree 
relatives 
with 
HBOC 
Average 
no. 2
nd
 
degree 
relatives 
with 
HBOC 
Averag
e no. 3
rd
 
degree 
relative
s with 
HBOC 
BRCA2 c.68-7T>A 5.25 3.15 -2.1 Acceptor unknown rs81002830 0.274 2 1.5 3.5 0 
BRCA2 c.9501+3A>T 9.04 4.55 -4.49 Donor unknown rs61757642 - 4 1.25 0.75 1 
BRCA1 c.4986+6T>G 3.58 2.25 -1.33 Donor yes rs80358086 - 1 2 1 0 
BRCA1 c.4357+6T>C 8.28 6.56 -1.72 Donor unknown rs80358143 - 1 1 1 2 
BRCA2 c.7007G>A 5.51 2.50 -3.01 Donor yes rs28897743 1.091 4 0.75 0.75 1 
BRCA1 c.5406A>C 6.05 4.15 -1.9 Donor - - - 1 1 0 0 
BRCA1 c.591C>T 10.4 8.8 -1.6 Donor unknown rs1799965 0.074 1 1 0 2 
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3.2 Estimation of number of breast cancer families with BRCA1 
and BRCA2 variants using a Power Analysis 
 
Previous literature has suggested a higher prevalence of deleterious BRCA1 and BRCA2 
variants in patients with family history of breast cancer compared to the LHSC patient 
cohort (57-100% vs. 3.6-35.7%) 
27
. After publishing and prioritizing BRCA1 and BRCA2 
variants detected through routine sequencing on splicing in silico, a power analysis was 
conducted to estimate the number of patients with undetected deleterious BRCA1 and 
BRCA2 mutations with 80% power and p<0.05. The number of deleterious variants 
detected in patients with varying family history of breast cancer as described in column 2 
of Table 6 was compared with published BRCA1 and BRCA2 linkage frequency in 
patients with familial breast cancer 
26
, as described in Chapter 2.2.  Proband pedigree 
information was only available for patients within certain family history groups (Groups: 
5-10).  Results indicate that the fraction of undetected BRCA1 and BRCA2 pathogenic 
variants across all groups ranges from 0.364 to 0.78, and the predicted minimum sample 
size needed to detect a BRCA1 and BRCA2 variant across all groups is 13 (Groups 5 and 
10).  Therefore to improve deleterious variant detection, whole gene sequencing should 
be employed to probe regions unexamined during routine sequencing.   
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Table 6. Estimation of number of breast cancer families with BRCA1 and BRCA2 variants using a Power Analysis 
Group Definition No. 
Eligible 
Patients 
Estimation of 
fraction of families 
with BRCA1 and 
BRCA2 variants 
Fraction of Detected 
BRCA1 and BRCA2 
variants 
Fraction of 
undetected 
variants 
Estimated no. 
patients with 
undetected 
mutations 
Minimum sample 
size for BRCA1 
and BRCA2 
variant 
detection* 
5 Breast cancer under 60, 
and a 1st or 2nd degree 
relative with ovarian or 
male breast cancer 
65 0.91 0.13 0.78 51 13 
6 Breast and ovarian 
cancer in the same 
individual, or bilateral 
breast cancer with first 
case before 50 
37 0.57 0.206 0.364 14 24 
7 Two cases of breast 
cancer, both before 50, 
in 1st or 2nd degree 
relatives 
93 0.7173 0.133 0.5843 55 16 
8 Two cases of ovarian 
cancer, any age, if 1st 
and 2nd degree relatives 
4 1 0.357 0.643 3 15 
10 Three or more cases of 
breast or ovarian cancer 
at any age on the same 
side of the family 
213 0.784 0.036 0.748 159 13 
Total no. 
family 
pedigrees 
 412      
* Using “fraction undetected” (Column 6) as an effect size
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3.3 Mini-gene transfection assays of prioritized putative BRCA1 
and BRCA2 splicing variants 
 
After prioritizing variants of unknown significance for effects on splicing using 
information theory-based analysis and the Human Splicing Finder, a recombinant mini-
gene transfection assay was designed as described in Chapter 2.1.2-2.1.6 to examine the 
effects of BRCA1:c.288C>T, BRCA2:c.7319A>G and BRCA1:c.548-16G>A variants on 
mRNA splicing.  Variants producing splicing changes predicted in Chapter 3.1 (Figure 5) 
will have the following corresponding effects on this mini-gene transfection assay: 1) 
BRCA1:c.288C>T would result in pcDNA-Dup mini-gene cassette exon skipping, 
whereas WT BRCA1:c.288C would result in cassette-exon inclusion, 2) 
BRCA2:c.7319A>G would result in pCAS2 mini-gene middle exon truncation from 
427bp to 326bp, whereas mini-gene middle exon containing WT BRCA2c.7319A would 
remain 427bp.  Finally, 3) BRCA1:c.548-16G>A would result in pCAS2 mini-gene 
middle exon elongation from 46bp to 60bp, whereas mini-gene middle exon containing 
WT BRCA1:c.548-16G would remain 46bp.  After transfection of recombinant mini-gene 
containing plasmids into MDA-MB-231 cells, total RNA was extracted, treated with 
DNase I and reverse transcribed.  Expected amplicon sizes of all resultant RT-PCR 
products are given when each experiment is described.   
 
cDNA products corresponding to WT BRCA1:c.548-16G>A and BRCA2:c.7319A>G 
were PCR amplified for 30 cycles using primers specific to the first and last exon of 
pCAS2 mini-gene (Table 1, primer identifier numbers 5 and 6) as recommended by 
INSERM.  PCR products were electrophoresed on 2% agarose gel.  Expected amplicon 
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size of BRCA1:c.548-16G WT mini-gene cDNA is 280bp and expected amplicon size of 
BRCA2:c.7319A WT mini-gene cDNA is 663bp.  Non-specific, low molecular weight 
fragments of ~100bp were observed in all conditions corresponding to both 
BRCA1:c.548-16G and BRCA2:c.7319A WT cDNA amplified both with and without 1M 
betaine at 57°C and 55°C annealing temperatures.  DNA fragments corresponding to 
mini-gene specific cDNA were not observed.   
 
pcDNA-Dup cDNA (empty pcDNA-Dup, WT BRCA1:c.288C>T, mutant 
BRCA1:c.288C>T) was PCR amplified using primers specific to mini-gene insert as 
given by collaborators at INSERM and described in Chapter 2.1.6.  PCR products were 
electrophoresed on a 2.5% agarose gel, shown in Figure 6.  The expected amplicon size 
of pcDNA-Dup mini-gene containing cassette exon is 304bp, and the expected amplicon 
size of mini-gene not containing cassette exon is 246bp.  DNA fragments greater than 
500bp were observed in all conditions.  Faint DNA fragments at sizes between 300bp and 
400bp are also observed in all conditions.  This may be an artifact corresponding to single 
stranded DNA derived from non-duplex mini-gene amplicon.  Investigating the identity 
of fragments >500bp revealed that the expected amplicon sizes of WT, mutant and empty 
pcDNA-Dup containing both exons and introns are 567bp, 567bp and 559bp respectively, 
which are approximately the sizes of fragments observed in Figure 6.  One explanation 
for the detection of fragments containing both intronic and exonic sequences is PCR 
amplification of cDNA derived from unspliced heteronuclear RNA transcribed from 
pcDNA-Dup mini-gene.  A more detailed explanation of this is discussed in Chapter 4.2.  
Another possible explanation that was investigated is plasmid DNA contamination.   
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To investigate the role of plasmid DNA contamination and DNase I digestion efficiency 
in amplification of mini-gene cDNA containing introns (Figure 6), varying 
concentrations of stock pcDNA-Dup plasmid DNA were digested with DNase I using the 
same procedure used on RNA samples, as described in Chapter 2.1.6.  Products of DNase 
I digestion were PCR amplified for 35 cycles using the same primers used to amplify 
pcDNA-Dup mini-gene cDNA.  If residual plasmid DNA remained after treatment with 
DNase I, the expected amplicon size of PCR product is 559bp.  If DNase I digestion ran 
to completion, then no template would be present for subsequent PCR reaction, and no 
fragments would be visualized after gel electrophoresis.  pcDNA-Dup plasmid DNA, 
DNase I treated pcDNA-Dup plasmid, and PCR amplification products of DNase I 
treated pcDNA-Dup plasmid were electrophoresed on a 1.5% agarose gel.  DNA 
fragments corresponding to plasmid DNA disappeared in all plasmid template 
concentration conditions after DNase I digestion (see Figure 7, Lane 2, 5, 8 and 11).  
However when DNase I treated plasmids were PCR amplified using mini-gene specific 
primers, faint fragments corresponding to the size of pcDNA-Dup mini-gene amplicon, 
as observed previously in Figure 10, were observed in all conditions (see Figure 7, Lane 
3, 6, 9 and 12), indicating residual plasmid DNA remained after DNase I digestion, which 
was subsequently PCR amplified and detected using gel electrophoresis.  
 
A second PCR amplification on DNase I digested pcDNA-Dup plasmid using the same 
mini-gene specific primers was performed for 25 cycles, products were electrophoresed 
on a 2.5% gel alongside products from 35 cycles amplification (see Figure 8).  This 
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shows that mini-gene specific PCR amplicon derived from DNase I digested pcDNA-
Dup plasmid was detectable at fewer PCR amplification cycles than performed on cDNA 
derived from RNA extracted from MDA-MB-231 cells.  This indicates that it may be 
possible that PCR amplification of mini-gene derived from plasmid DNA contamination 
account for fragments observed above 500bp in Figure 10.  However, fragments 
corresponding to PCR amplified, DNase I treated pcDNA-Dup in Figure 7 and 8 are very 
faint after 35 and 25 cycles of amplification compared to plasmid DNA loaded in known 
concentrations shown in Figure 7.  Therefore, although plasmid DNA may account for 
residual amounts of fragments observed in Figure 6, the identity of these fragments are 
likely due to RT-PCR of unspliced hnRNA template.   
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       1             2            3 
 
Figure 6. RT-PCR of DNase I treated pcDNA-Dup mini-gene RNA extracted from 
transfected MDA-MB-231 cells using primers recommended by INSERM.  Numbers 
above all gel images presented in this section indicate lane number, and numbers beside 
images indicate DNA molecular weight marker.  Lane 1 (empty pcDNA-Dup, expected 
amplicon size without cassette exon: 246bp), Lane 2 (WT BRCA1:c.288C>T, expected 
amplicon size with cassette exon: 304 bp), Lane 3 (mutant BRCA1:c.288C>T, expected 
amplicon size without cassette exon: 246 bp).  Fragments above 500 bp were observed in 
all conditions.  Faint DNA fragments at sizes between 300bp and 400bp are also 
observed in all conditions.  This may be an artifact corresponding to single stranded DNA 
derived from non-duplex mini-gene amplicon. The expected amplicon sizes of WT, 
mutant and empty pcDNA-Dup mini-gene containing both exons and introns are 567bp, 
567bp and 559bp respectively.   
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Figure 7. DNase I digestion of stock pcDNA-Dup plasmid and subsequent PCR 
amplification.  pcDNA-Dup plasmid of varying concentrations was electrophoresed on a 
1.5% gel (Lane 1: 440ng, Lane 4: 220ng, Lane 7: 110ng, Lane 10: 20ng).  The same 
concentration of pcDNA-Dup plasmid was treated with DNase I as described in Chapter 
2.1.6 (Lane 2: 440ng, Lane 5: 220ng, Lane 8: 110ng, Lane 11: 20ng).  DNase I digested 
plasmid DNA of each concentration was PCR amplified using primers specific to mini-
gene insert for 35 cycles (Lane 3: 440ng, Lane 6: 220ng, Lane 9: 110ng, Lane 12: 20ng), 
fragments corresponding to the expected size of mini-gene amplicon were observed in all 
conditions (559 bp). 
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Figure 8. 35 and 25 cycle PCR amplification of pcDNA-Dup mini-gene following 
DNase I digestion.  Varying concentrations of pcDNA-Dup plasmid were digested with 
DNase I and PCR amplified for 35 and 25 cycles using primers specific to mini-gene.  
Fragments corresponding to the expected size of mini-gene amplicon (559 bp) were 
observed in all conditions in both 35 cycle and 25 cycle PCR amplification (Lane 1: 
440ng template, 35 cycles, Lane 2: 440ng template, 25 cycles, Lane 3: 220ng template, 
35 cycles, Lane 4: 220ng template, 25 cycles, Lane 5: 110ng template, 35 cycles, Lane 6: 
110ng template, 25 cycles, Lane 7: 20ng template, 35 cycles, Lane 8: 20ng template, 25 
cycles).  
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Following the PCR amplification reactions described previously, primers were designed 
to span exon-exon junctions to selectively amplify spliced mini-gene cDNA.  PCR 
amplification of WT and mutant mini-gene transcripts corresponding to 
BRCA2:c.7319A>G was conducted as described in Chapter 2.1.6.  Expected amplicon 
sizes for BRCA2:c.7319A>G pCAS2 mini-gene cDNA: containing middle exon is 610bp, 
and with hypothesized truncated middle exon is 667 bp. Products were resolved on a 2% 
agarose gel.  Faint low molecular weight DNA fragments were observed in 
BRCA2:c.7319A>G WT and mutant conditions amplified using primers designed to 
amplify mini-gene with no/aberrant middle exon (primer identifiers 9 and 10 in Table 1).  
Mini-gene specific DNA fragments were not observed in any conditions.  No fragments 
were observed in both WT and mutant conditions amplified using primers specific to 
mini-gene with middle exon (primer identifiers 11 and 12 in Table 1).  Following this, 
PCR amplification was conducted at lower annealing temperatures of 53°C and 54°C for 
primers 11 and 12 and 55°C and 56°C for primers 9 and 10.  Products were resolved on a 
2% gel.  Low molecular weight DNA fragments of the same size were observed in all 
conditions.  However, mini-gene specific DNA fragments were not observed in any 
conditions. 
 
Next, primers specific to amplify pcDNA-Dup containing cassette exon (primer identifier 
numbers 3 and 4 in Table 1) and not containing cassette exon (primer identifier numbers 
1 and 2 in Table 1) were used to PCR amplify pcDNA-Dup mini-gene cDNA.  Products 
were resolved on a 2.5% agarose gel, as shown in Figure 9.  cDNA fragments appearing 
at sizes corresponding to both cassette exon inclusion and exclusion in both 
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BRCA1:c.288C>T WT and mutant conditions were observed after resolving PCR 
products on a 2% agarose gel, as shown in Figure 9.  Therefore mini-gene transcripts 
containing both WT and mutant BRCA1:c.288C>T appear to undergo leaky splicing in 
MDA-MB-231 breast cancer cell line.  
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Figure 9.  PCR amplification of empty pcDNA-Dup, BRCA1:c.288C>T WT and 
mutant cDNA.  BRCA1:c.288C WT and BRCA1:c.288C>T Mutant mini-gene cDNA 
was PCR amplified using primers specific to amplify mini-gene containing cassette exon 
(Lane 1 and 2 respectively). Empty pcDNA-Dup, BRCA1:c.288C WT and 
BRCA1:c.288C>T Mutant mini-gene cDNA was also PCR amplified using primers 
specific to mini-gene not containing cassette exon (Lane 4, 5 and 6 respectively). 
Fragments appear at expected size of 63bp in WT and mutant condition (Lane 1 and 2 
respectively).   Fragments also appear at expected size of 209bp in WT, mutant and 
empty pcDNA-Dup conditions (Lanes 4, 5 and 6).  A 50bp ladder (Lane 3) was used to 
approximate fragment sizes.  PCR and gel electrophoresis indicates both WT and mutant 
conditions show partial cassette exon skipping.   
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Cassette exon exclusion of WT pcDNA-Dup cDNA (Figure 9) and initial RT-PCR 
fragments corresponding to mini-gene template containing intronic and exonic sequences 
(Figure 6), suggest splicing of transfected pcDNA-Dup plasmid is not efficient (see 
Chapter 4.2 for discussion).  Therefore the hypothesis that BRCA1:c.288C>T leads to 
cassette exon skipping as a result of abolishing SRp40 and SF2/ASF ESE elements can 
neither be supported nor rejected based on these results.   
 
cDNA corresponding to WT BRCA2:c.7319A>G and BRCA1:c.548-16G>A at 3:1 
transfection ratios were PCR amplified as described in Chapter 2.1.6.  Products were 
electrophoresed on a 2% agarose gel.  Expected amplicon size for BRCA1:c.548-16G>A 
mini-gene cDNA containing middle exon is 220bp, not containing middle exon is 280bp.  
Expected amplicon size for BRCA2:c.7319A>G cDNA containing middle exon is 610bp, 
not containing middle exon is 280bp, and containing truncated middle exon is 667bp.  
Faint low molecular weight fragments were observed in all conditions.  Fragments 
corresponding to mini-gene specific cDNA were not observed in any conditions.   
 
Before the preceding RT-PCR experiments were conducted, DNase I treated reverse 
transcribed RNA extracted from all 1.5:1 transfection ratio WT and mutant conditions (in 
the presence of puromycin) as well as control HapMap cDNA from a previous study, 
were PCR amplified using primers specific to cDNA derived from stable gene VSP39 to 
ensure RNA extraction and reverse transcription procedures were successful.  Results are 
shown in Figure 10.  DNA fragments corresponding to expected amplicon sizes of 103bp 
were observed in all conditions, Lane 7 corresponding to BRCA1:c.548-16G>A mutant 
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condition intensity is very faint.  An additional control will be required to verify that 
RNA extraction and RT-PCR was successful in this condition.  This is described in the 
following paragraph.  Another PCR reaction designed to amplify VSP39 cDNA under the 
same conditions was conducted on 1.5:1 transfection ratio pcDNA-Dup plasmid 
conditions (with puromycin) including empty pcDNA-Dup, BRCA1:c.288C WT and 
BRCA1:c.288C>T mutant because amplification data for BRCA1:c.288C WT condition is 
not presented in Figure 10 (see Figure 11).  Presence of fragments at expected sizes 
indicate that VSP39 is spliced in MDA-MB-231 cells and RNA extraction and RT-PCR 
protocols were successful.   
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Figure 10. VSP39 cDNA amplification of 1.5:1 transfection ratio samples and 
control HapMap (GM19200) cDNA.  PCR products of cDNA corresponding to the 
following transfection conditions: empty pCAS2 (Lane 1), BRCA2:c.7319A WT (Lane 
2), BRCA2:c.7319A>G Mutant (Lane 3), empty pcDNA-Dup (Lane 4), 
BRCA1:c.288C>T Mutant (Lane 5), BRCA1:c.548-16G WT (Lane 6), BRCA1:c.548-
16G>A Mutant (Lane 7), GM19200 (Lane 8) was electrophoresed on a 2% agarose gel.  
Fragments corresponding to expected amplicon sizes of 103bp were observed in all 
conditions, Lane 7 corresponding to BRCA1:c.548-16G>A Mutant condition intensity is 
faint..    
 
 
 
 
 
Figure 11. VSP39 cDNA amplification of 1.5:1 transfection ratio pcDNA-Dup 
samples.  PCR products of cDNA corresponding to empty pcDNA-Dup (Lane 1),  
BRCA1:c.288C WT (Lane 2) and BRCA1:c.288C>T Mutant (Lane 3) was 
electrophoresed on a 2% agarose gel.  Fragments corresponding to expected amplicon 
sizes of 103bp were observed in all conditions. 
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cDNA from an additional endogenously expressed gene, BRCA2, was PCR amplified to 
confirm the success of RNA extraction and RT-PCR.   DNase I treated reverse 
transcribed RNA extracted from all 1.5:1 transfection ratio WT and mutant conditions (in 
the presence of puromycin) was PCR amplified using primers spanning the BRCA2 
exon11-12 junction as described in Chapter 2.1.6.  The expected amplicon size for these 
products is 96bp.  PCR products were electrophoresed on a 2% agarose gel, shown in 
Figure 12.  Fragments of the expected size are seen in all conditions, indicating splicing 
of BRCA2 mRNA in MDA-MB-231 cells, and successful RNA extraction and reverse-
transcription in each condition. 
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Figure 12.  BRCA2 cDNA amplification of 1.5:1 transfection ratio (with puromycin). 
PCR products of cDNA corresponding to the following transfection conditions: empty 
pcDNA-Dup (Lane 1), empty pCAS2 (Lane 2), BRCA1:c.288C WT (Lane 3), 
BRCA1:c.288C>T Mutant (Lane 4), BRCA1:c.548-16G WT (Lane 5), BRCA1:c.548-
16G>A Mutant (Lane 6), BRCA2:c.7319A WT (Lane 7), BRCA2:c.7319A>G Mutant 
(Lane 8) was electrophoresed on a 2% agarose gel.   A 50bp DNA ladder was loaded into 
Lane 2, 50bp and 100bp markers are annotated.  DNA fragments of varying intensities 
are observed at expected size of 96 bp.  A second, non-specific PCR product above the 
50bp band on the ladder is observed in the empty pcDNA-Dup condition. 
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3.4 Capture Array design and synthesis  
 
 
Twenty-four thousand, 36-70mer oligonucleotide probes were designed to capture seven 
breast cancer associated genes and adjacent intergenic regions for downstream 
sequencing.  Tiling-array tracks displaying designed probes targeting regions of interest 
are displayed in Figure 13.  Gaps in coverage are non-single copy regions, as determined 
using the ab initio method described in Chapter 2.4, and include interspersed repetitive 
regions such as: short interspersed nuclear elements (SINE), long interspersed nuclear 
elements (LINE), microsatellites, long terminal repeats (LTR) etc.  Table 7 displays the 
percentage of each gene covered by probes. 
 
Table 7. Percent probe coverage across each gene 
Gene Percent 
coverage 
across gene 
and 10kb 
intergenic 
region (%) 
Percent 
exon 
coverage 
(%) 
Percent 
UTR 
coverage 
(%) 
Percent 
intronic 
coverage 
(%) 
Percent 
intergenic 
coverage 
(%) 
ATM 60.7 97.1 73.9 56.7 64.4 
BRCA1 47.5 96.1 72.1 27.6 50.9 
BRCA2 66.6 97.4 79.1 59.6 75.4 
CDH1 47.3 99.3 61.8 47.9 35.6 
CHEK2 32.6 71.8 29.7 31.8 62.3 
PALB2 38.4 93.9 86.9 39.1 26.2 
TP53 49.0 91.9 78.7 37.2 53.0 
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Figure 13.  Target-enrichment probe tiling arrays.  BED tracks showing probes 
designed to target seven breast cancer associated genes and 10kb of adjacent intergenic 
regions (shown in black bars above gene).  Gaps in coverage are non-single copy regions.   
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A total of 7869 variants were called in all 21 sequenced patients using Picard and GATK 
after using binomial calculator to determine putative false positive variants as described 
in Chapter 2.6.  When accounting for common variants detected in multiple patients, a 
total of 2871 unique variants were detected, 1504 of which are previously identified 
SNPs (dbSNP and HapMap).  Variants were found throughout each gene and adjacent 
intergenic regions (+10 kbp), as shown in Table 8.  
 
Table 8. Variant location and average base coverage  
Gene Upstream 
of Gene 
5’ UTR Intron Exon 3’ UTR Downstream 
of Gene 
Avg. base 
coverage 
per 
variant 
ATM 106 12 1299 26 38 67 32.8 
BRCA1 131 1 749 68 19 124 32.6 
BRCA2 202 6 958 83 19 135 35.5 
CDH1 284 0 1554 13 18 89 36.2 
CHEK2 87 0 762 71 0 56 23.5 
PALB2 36 0 177 7 0 58 25.4 
TP53 90 1 174 25 14 350 42.2 
 
Each of three separate sequencing runs achieved higher variant coverage than the run 
previous, with the first sequencing run attaining an average of 4.46x variant coverage, the 
second, 15.3x variant coverage and third, 47.93x variant base coverage.  After all variants 
were identified and filtered to exclude putative false positives, coding and adjacent 
intronic SNP’s detected by the Molecular Diagnostics Laboratory were examined in our 
targeted sequencing data to determine the number of corroborated SNPs.  The results are 
shown in Table 9.  In the first sequencing run, 1/22 BRCA1 and BRCA2 SNPs identified 
by the Molecular Diagnostics Laboratory were detected.  The reason for low concordancy 
is inadequate base coverage.  Although coverage improved in the second sequencing run, 
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still only 15/49 SNPs were validated.  However, sequencing DNA samples prepared 
using Agencourt magnetic beads in the final run, as described in Chapter 2.5, validated 
81/81 SNPs, thus highlighting the significance sample loss resulting from gel extraction, 
column purification and sample transfer on sequencing coverage, and reliable variant 
detection.  This increase in coverage can also be attributed to longer sequencing reads 
(from 36>50bp paired-end reads) and an Illumina imaging software upgrade.   
 
A second BED track displaying captured and sequenced regions was created is displayed 
below each probe design tiling-array track in Figure 14.  Sequencing reads aligned to 
greater than 99% of regions containing probes.   However, sequenced regions aligned to 
non-target areas as well, including repetitive regions in the targeted genes due to capture 
of sequences spanning both single copy regions hybridizing to probe, and repetitive 
regions that are paired-end sequenced and aligned to both on-target single-copy and off-
target repetitive regions.  In addition, some reads aligned to regions outside of the 
targeted areas.  One potential cause of this is what has been termed, “daisy-chaining”, 
and is the result of repetitive regions on a DNA fragment encoding a probe-specific 
single copy sequence binding to a complementary repetitive sequence on a DNA 
fragment that is off-target 
91
.  Although COT-1 DNA has been used during hybridization 
to compete with off-target repetitive sequences for binding on-target DNA fragments 
harboring repeats, off-target repetitive regions binding to on-target DNA cannot be 
prevented with 100% efficiency.   Additionally, DNA fragments containing segments of 
segmental duplicons mapping to both on-target and off-target regions may bind probes 
with high enough affinity to be captured and sequenced.  Also, post-hybridization wash 
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steps are designed to be stringent enough to prevent washing away DNA fragments 
bound to RNA probes with high affinity, but not so stringent as to wash away on-target 
DNA fragments binding with moderate affinity.  Therefore, it is possible that residual 
amounts of off-target, non-specifically bound DNA is retained during wash steps.   
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Table 9.  Validation of BRCA1 and BRCA2 SNPs detected by Molecular Diagnostics Laboratory.  
BRCA1 
region 
Intron 8 Exon 11 Exon 13 Exon 16 Intron 16 Intron 17 Exon 18 Intron 18   
Variants 
validated 
0/2 38/54 7/10 7/11 0/4 0/1 1/1 1/1   
BRCA2 
region 
5’ UTR Exon 3 Intron 4 Exon 10 Intron 11 Exon 11 Exon 14 Intron 14 Intron 16 Exon 22 
Variants 
validated 
0/1 1/1 0/1 11/16 0/1 20/32 2/2 0/1 8/13 1/1 
 
*First sequencing run: 1/22 BRCA1 and BRCA2 SNPs previously detected by the Molecular Diagnostics Laboratory were 
validated; second sequencing run: 15/49 SNPs validated; third sequencing run: 81/81 SNPs validated. 
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Figure 14.  Target enrichment probe tiling array and captured sequence tracks. 
Tracks of seven breast cancer associated genes (top track), tiling-array probe regions 
(second track), and captured and sequenced DNA (third track). 
 
Identified variants were analyzed for effects on: splicing, TFBS, and 5’ and 3’ UTR 
structure and RBPBS, amino acids and miRNA binding sites.  All variants were inputted 
into the Shannon pipeline to examine putative effects on canonical splice sites.   Of 7869 
variants submitted, 2052 variants lead to changes in information content of natural and 
cryptic donor and acceptor sites.  These variants were prioritized for effects on splicing 
based on the criteria described in Chapter 2.2.4.  The majority of variants (1898) altered 
the information content of cryptic intronic splice sites.  Of these variants, 449 had a final 
information content less than that of the nearest natural splice site and are unlikely to 
bind the spliceosome with greater affinity than the natural site and were thus disregarded.  
However, 61 variants resulted in an information content greater than the most proximal 
natural site.  Fourteen of these variants were within 300bp of the natural splice site and 
BRCA2 
CDH1 
ATM 
CHEK2 
PALB2 
TP53 
BRCA1 
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were prioritized.  Of 2052 variants, 138 resulted in changes in information content of 
exonic cryptic splice sites, however, all occurred >300bp from the natural splice site, and 
none resulted in the creation of a cryptic site of greater information content than the 
natural splice site and so, were not prioritized.  Finally, 15 variants were found to alter 
natural splice site information content, 11 of which strengthened natural splice sites by 
1.12, 1.33 and 1.72 bits and were not prioritized. Three of these variants resulted in 
reduced splice site information content, and one variant abolished a natural acceptor site.  
Table 10 displays the final list of variants prioritized for splicing effects, as well as the 
site affected by the variant, the initial and final information content of the splice site 
affected, the SNP associated with the variant (if applicable), base coverage associated 
with the variant and the information content of the nearest natural splice site in the case 
of variants creating cryptic splice sites. 
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Table 10. Prioritized putative splicing variants in 21 breast cancer patients. 
Gene Variant (HGVS) Ri 
initial 
(bits) 
Ri final 
(bits) 
ΔRi Type Ri of 
nearest 
natural 
site 
rsID Alt. Allele 
population 
frequency 
(dbSNP) 
Coverage
1 
Inactivating Natural Splice Site Variants (Ri final <1.6 bits)  
PALB2 c.2997-1G>A 7.41 -3.47 -10.88 Acceptor - - - 6 
Leaky Natural Splice Site Variants (Ri final >1.6 bits)   
ATM c.3403-12T>A 9.81 7.21 -2.6 Acceptor - - - 4 
BRCA2 c.9502-909A>T 
2
 19.87 12.17 -7.7 Acceptor - - - 5 
BRCA1 c.4358-2801T>A
3
 10.17 8.32 -1.85 Acceptor - - - 20 
Cryptic Splice Site Strengthening Variants (Ri final equivalent or greater than natural site Ri)  
ATM c.6199-61C>G -11.2 0.5 11.7 Acceptor -1.14 - - 6 
BRCA2 c.197T>C * 0.63 1.75 1.12 Acceptor 1.72 rs4942486 0.468 15, 6, 6, 
48, 105, 
89, 28, 64, 
78 
PALB2 c.3351-49T>A 5.76 13.46 7.7 Acceptor 9.03 - - 4 
BRCA1 c.548-24A>T 0.14 2.32 2.18 Acceptor 0.49 - - 4 
CHEK2 c.-6-98C>T 9.41 10.5 1.09 Acceptor 1.76 rs73881129 No data 25, 81 
* Sanger sequencing validated 
1
Variants with more than one coverage value are found in multiple patients 
2
 EST BE869603 
3
 26nt upstream of acceptor in BRCA1 uc002ict.3 transcript 
 
113 
 
All identified variants were then examined for effects on TFBS’s in silico as described in 
Chapter 2.2.4.  After all changes in information content were calculated using the 
“Mutation Analysis” program, variants were filtered to include only those affecting 
particular TFBS’s with information contents greater than one standard deviation above 
the mean information content for that TFBS.  The total number of putative TFBS altering 
variants was reduced to 3108.  Next, variants were filtered using HMEC mammary 
epithelial cell line DNase I HS HotSpot data from ENCODE; putative TFBS variants 
were reduced from 3108 to 228.  Variants were then filtered for presence within 10kb of 
transcription start site (TSS), which reduced the number of putative TFBS variants from 
228 to 48.  Variants were then prioritized based on change in information content (>1.0 
bits) and proximity to TSS.  A final list of variants prioritized for effects on TFBS, 
including the change in information content, rsID’s associated with variant, variant 
coverage, and proximity to TSS, are shown in Table 11.  Transcription factor binding 
sites affected by the variants presented in Table 11 have been shown to be influential in 
breast cancer etiology.  
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Table 11. Prioritized variants altering TFBS information content 
Gene Variant (HGVS) Transcription 
Factor 
Ri 
initial 
(bits) 
Ri 
final 
(bits) 
ΔRi Distance 
from 
TSS
1 
rsID Alternate 
allele 
population 
frequency 
(dbSNP) 
Coverage
3 
CHEK2 c.-346T>C HSF1 9.5 -1.6 -11.1 271 rs200681712 No data 8, 69, 206 
CDH1 c.48+76C>T HSF1 9.5 -0.9 -10.4 251 - - 15 
CHEK2 c.-346T>C BCLAF 10.0 0.4 -9.6 282 rs200681712 No data 8, 69, 206 
ATM c.-1520G>A GRP20 6.3 -3.3 -9.6 1129 rs190491586 No data 4 
CDH1 c.163+1880G>T TCF7L2 10.3 1.2 -9.1 2999 - - 5 
CDH1 c.163+1757A>T YY1 9.7 8.4 -1.3 2880 - - 6 
ATM
 c.-365C>G ETS1
2 
5.7 -3 -8.7 22 - - 29 
CDH1 c.48+136C>G EBF1
2 
6.9 0.8 -6.0 305 rs36037011 No data 18, 34 
CDH1 c.163+1771A>G GATA3
2 
7.4 5.6 -1.8 2897 - - 20 
BRCA1 c.-20G>T TCF7L2
2 
6.7 5 -1.7 203 - - 5 
1
Italicized Distances are downstream of TSS 
2
TFBS initial Ri is below Mean Ri  
3
Variants with more than one coverage value listed were found in multiple patients 
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Variants within 5’ and 3’ UTRs were then examined in silico for effects on mRNA 
structure using SNPfold.  Altering UTR mRNA structure can affect translation initiation 
and influence disease 
92
.  Both UTR regions have been submitted to Alain Laederach’s 
lab at UNC Chapel Hill for SHAPE analysis as described in Chapter 1.7, to validate 
SNPfold predictions on RNA structure alterations.  Both variants predicted to alter 
structure were subsequently examined for effects on RBPBS’s.  Variants are shown in 
Table 12.   RNA-binding protein binding sites altered include an abolished SNRPA 
binding site (the U1 snRNP of spliceosome), as a result of the 5’ UTR variant, and a 
strengthened cryptic SF2/ASF binding site (3’ UTR variant).  
 
Variants in 3’ UTRs were inputted into SNPNexus while selecting for predicted effects 
on miRNA binding.  No variants were predicted to affect miRNA binding.  Next, 
predicted miRNA binding sites in BRCA1 and BRCA2 were examined using 
TargetScanHuman 
79
, and mapped to BRCA1 and BRCA2 3’ UTR regions on the UCSC 
genome browser.  No miRNA’s were predicted to bind to BRCA2 3’ UTR, whereas 5 
putative miRNA binding sites were found on BRCA1 3’ UTR, including: miR-7/7ab 
(chr17:41196419-41196425), miR-132/212 (chr17:41196447-41196453), miR-205 
(chr17:41196487-41196493), miR-125a-3p (chr17:41197454-41197461), and miR-218 
(chr17:41197477-41197483).  miRNA binding sites were also examined using the 
miRBase through the UCSC Genome browser snoRNA/miRNA gene prediction track. 
No variants were found within predicted miRNA binding sites identified through either 
TargetScan or miRBase. 
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Table 12. Variants predicted to affect UTR mRNA structure and RNA-binding protein binding sites 
Gene Variant 
(HGVS) 
UTR rsID Alternate 
allele 
population 
frequency 
(dbSNP) 
SNPfold 
rank 
p-value RBPBS Ri 
initial 
(bits) 
Ri 
final 
(bits) 
ΔRi Coverage
1 
BRCA2 c.-52A>G * 5’  rs206118 0.156 2/900 0.0022 SNRPA 8.2 4.4 -3.8 17, 107, 54 
BRCA2 c.*369A>G * 3’  rs7334543 0.231 241/4500 0.0535 SF2/ASF 0.68 4.8 4.2 30, 37, 30, 2 
*Sanger sequencing validated 
1
Variants with more than one coverage value indicate the variant was found in multiple patient samples, each with a unique coverage 
value  
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A total of 293 exonic variants were detected in all patients, which were subsequently 
sorted based on SNP alternate allele population frequency and variant coverage. This was 
done with the assumption that variants with lower alternate allele population frequencies 
have a greater likelihood of influencing disease etiology than those with high alternate 
allele population frequency. Results of sorted variants are shown in Table 13.  Variants 
presented in Table 13 were not predicted to result in splicing or TFBS changes.  One 
variant has been reported previously by the Molecular Diagnostics Laboratory 
(BRCA1:c.5136G>A) to result in a protein truncation, and was included in this study as a 
positive control.  Another variant resulting in a missense change (PALB2:c.2993G>A) 
predicted to affect protein function by PolyPhen and SIFT as has been reported by 
Hellebrand H. et al. (2011) and found to be prevalent in both patients with breast cancer 
and healthy controls in three independent studies, and is not likely to be influential in 
breast cancer etiology 
93,94
.  An additional putative variant leading to a premature stop 
codon was identified in ATM (c.7051G>T), however this variant would need to be Sanger 
sequencing validated. 
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Table 13. Exonic variants filtered based on coverage, amino acid and SNP alternate 
allele population frequency 
Gene Variant (HGVS) Amino 
acid  
SNP  Alternate 
allele 
population 
frequency 
(dbSNP) 
Coverage 
ATM c.735C>T V>V rs3218674 0.007 41 
PALB2 c.2993G>A 
2 
G>E rs45551636 0.011 27 
PALB2 c.3300T>G T>T rs45516100 0.018 26 
BRCA1 c.5136G>A 
1 
W>Stop rs80357418 No data 16 
TP53 c.699C>A H>Q - - 15 
TP53 c.691A>C T>P - - 15 
BRCA2 c.1814T>A I>K rs80358468 No data 13 
ATM c.7051G>T E>Stop - - 12 
ATM c.146C>G S>C rs1800054 0.006 11 
CHEK2 c.1298A>G Y>C - - 11 
1
Also detected by Molecular Diagnostics Laboratory at LHSC 
2
 VUS reported by Hellebrand H. et al. (2011), found in both breast cancer patient and control 
samples.  PolyPhen, SIFT and MutationTaster predict variant affects protein function. 
 
 
After putative splicing, TFBS, and 5’ and 3’ UTR affecting variants were PCR amplified 
and sent for Sanger sequencing validation, three were confirmed and include putative 
UTR affecting variants:  BRCA2:c.-52A>G, BRCA2:c.*369A>G, as well as putative 
splicing variant: BRCA2:c.197T>C.  Putative effects of these variants on disease are 
discussed in Chapter 4.4. 
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Chapter 4 Discussion 
4.1 Project summary 
 
Familial breast cancer is a complex disease with multiple genes associated with its 
etiology 
7,29
.  High penetrant breast cancer associated genes BRCA1 and BRCA2 were 
first discovered through familial linkage analyses 
3,6
 and account for approximately 13% 
of total familial breast cancer cases 
7
.  Subsequent association studies have identified 
other low to moderate penetrant genes associated with breast cancer, including: ATM, 
CDH1, CHEK2, PALB2, and an additional high penetrant gene TP53, the gene products 
of which are involved in the double strand DNA break repair pathway and cell-to-cell 
adhesion (CDH1) 
29
.  
 
Currently, Molecular Diagnostics Laboratories in Ontario sequence coding and adjacent 
intronic regions (-20 to +10 bp around exons) of the high penetrant breast cancer 
associated genes BRCA1 and BRCA2 in individuals with a strong family history of breast 
cancer to detect deleterious variants.  A power analysis examining BRCA1 and BRCA2 
variant prevalence in individuals with family history of breast cancer was conducted to 
estimate the minimum number of individuals needed for whole gene sequencing to 
identify pathological BRCA1 and BRCA2 variants.  This revealed that many individuals 
with a family history of breast cancer are predicted to have undetected pathogenic 
variants in BRCA1 and BRCA2 (Table 6).  Therefore, regions outside of exons and 
adjacent introns (-20bp to +10bp) may harbor deleterious mutations.  Since variants in 
non-coding regions can affect: splicing, transcription factor binding, mRNA structure and 
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RBPBS, miRNA binding etc., sequencing whole genes is necessary to achieve more 
sensitive deleterious variant detection.  In addition to non-coding regions in BRCA1 and 
BRCA2, variants may be present in other genes associated with familial breast cancer.  To 
better detect deleterious variants in individuals with a family history of breast cancer, 
multiple low to high penetrant genes previously determined to be associated with breast 
cancer etiology need to be sequenced in their entirety, including adjacent intergenic 
regions.    
 
Based on the limitations of routine diagnostic sequencing of breast cancer patients in 
identifying deleterious variants, there are three aims to this study.  The first is to publish 
VUS previously detected by the Molecular Diagnostics Laboratory at LHSC to the 
ENIGMA consortium and to predict the effects of variants on splicing in silico and 
validate predictions using an ex vivo mini-gene assay.  The second aim is to investigate 
the deleterious variant detection limits of the molecular diagnostics through a power 
analysis, and to improve variant detection by sequencing coding, non-coding and 
adjacent intergenic regions (+10 kbp) of seven breast cancer associated genes, including: 
ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2 and TP53.  The final aim of this study is 
to prioritize variants detected in this sequencing study for effects on: splicing, 
transcription factor binding sites (TFBS), 5’ and 3’ UTR mRNA structure and RNA 
binding protein binding sites (RBPBS), and miRNA binding using in silico 
bioinformatics tools to reduce the number of clinically non-significant variants and select 
only those potentially influential in breast cancer etiology for future analyses to 
determine variant pathogenicity. 
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4.2 Aim 1: Variants of unknown significance publication and 
splicing analysis 
 
To facilitate the elucidation of variants of unknown significance detected by the 
molecular diagnostics lab, all variants were converted to HGVS nomenclature and 
submitted to the ENIGMA consortium.  Next, variants were prioritized in silico for 
effects on splicing.  Of 158 variants, two were prioritized for effects on splicing using the 
Automated Splice Site Analysis server and the Human Splicing Finder as described in 
Chapter 2.1.1, these variants include BRCA1:c.288C>T, predicted in silico to abolish 
splicing regulatory SRp40 and SF2/ASF binding sites 14 nucleotides upstream of natural 
donor site, and BRCA2:c.7319A>G, predicted in silico to create a cryptic SRp40 site 120 
nucleotides upstream of natural donor site, and in close proximity to a cryptic donor site 
of comparable information content to the natural donor (2.3 bits and 2.4 bits 
respectively).  Both variants, as well as a variant described by Mucaki et al. (2011) 
46
, 
BRCA1:c.548-16G>A, predicted in silico to create a cryptic acceptor site 14 nucleotides 
upstream of natural acceptor site, were examined for effects on splicing using a mini-
gene assay. 
 
Putative leaky splicing variants were also identified within the LHSC patient cohort and 
are displayed in Table 5.  To examine disease penetrance, pedigree information for all 
probands harboring a putative leaky splicing variant was obtained from LHSC.  The 
average number of 1
st
, 2
nd
 and 3
rd
 degree relatives with HBOC is reported in Table 5.   At 
least one patient with each variant has a 1
st
 degree relative with breast and/or ovarian 
cancer.  Based on information theory predictions and disease penetrance of 15 patients 
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with putative leaky splicing variants, each of these variants is likely to result in 
deleterious BRCA1/BRCA2 levels as a result of aberrant splicing, which is likely to be 
influential in hereditary breast and/or ovarian cancer predisposition.   
 
The BRCA1:c.4986+6T>G and BRCA2:c.7007G>A variants are listed as clinically 
significant in the BIC database, which supports their role in breast cancer etiology.  
Investigating putative leaky splicing variants of unknown clinical significance (BIC) in 
the literature revealed that BRCA2:c.68-7T>A, BRCA2:c.9501+3A>T and 
BRCA1:c.591C>T lead to aberrant splicing 
95–97
.  RT-PCR analysis of patient blood 
samples and lymphoblastoid cell lines by Muller et al. (2011) revealed that patients with 
the BRCA2:c.68-7T>A have 22% of total BRCA2 mRNA missing exon 3, compared to 
6% in WT controls 
95
.   However, they concluded that further co-segregation and 
case/control mutation frequency analyses are needed to characterize this variant as 
pathogenic, and recommend that the variant remain unclassified.  The 
BRCA2:c.9501+3A>T variant has been characterized as deleterious by Borg et al. (2010) 
due to segregation data and cDNA confirming BRCA2 exon 25 skipping, resulting in a 
frameshift and a pre-mature stop codon 
97
.  Finally, the BRCA1:c.591C>T variant has 
been shown by Dosil et al. (2010) to decrease the efficiency of intron 9 donor site 
recognition through RT-PCR of RNA extracted from patient peripheral blood 
lymphocytes. However, they characterize this variant as non-pathogenic because 
although they demonstrate that recognition of the intron 9 donor site is reduced, further 
analyses of patient-specific BRCA1 transcript revealed in-frame skipping of both exon 9 
and exon 10, which is a naturally occurring, non-pathogenic splice isoform of BRCA1  
96
.  
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Therefore based on patient family history of HBOC and the clinical significance of these 
variants as reported both in the literature and BIC database, the leaky splicing variants 
identified in the LHSC cohort that are likely to be influential in breast cancer etiology 
include: BRCA2:c.9501+3A>T, BRCA1:c.4986+6T>G and BRCA2:c.7007G>A, whereas 
BRCA1:c.591C>T is likely to be non-pathogenic.  And although patients with 
BRCA2:c.68-7T>A have a strong family history of HBOC as indicated in Table 5, and it 
has been shown that this variant promotes aberrant splicing, further case/control mutation 
frequency and segregation studies need to be conducted before this variant is labeled 
pathogenic, as recommended by Muller et al. (2011).   
 
Recombinant plasmids harboring WT and mutant mini-gene constructs corresponding to 
BRCA1:c.288C>T (pcDNA-Dup plasmid), BRCA2:c.7319A>G (pCAS2 plasmid) and 
BRCA1:c.548-16G>A (pCAS2 plasmid) were constructed and transfected into MDA-
MB-231 cell line to examine effects of variants on splicing (Chapter 2.1.2-2.1.6).  After 
transfection of all mini-gene plasmids, RNA was extracted, digested with DNase I and 
reverse transcribed.  First, RT-PCR products were PCR amplified to amplify cDNA from 
endogenously expressed VSP39 and BRCA2. Amplicons of expected sizes (103bp for 
VSP39 and 96bp for BRCA2 respectively) were observed in all plasmid conditions 
(Figures 10, 11 and 12).  This indicates that these transcripts are correctly spliced in 
MDA-MB-231 cells, and RNA extraction and reverse transcription experiments were 
successful.   
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Next, PCR amplification of cDNA corresponding to pcDNA-Dup transfection conditions 
yielded fragments each of approximately the same size at just greater than 500bp (Figure 
6).  The expected amplicon size of pcDNA-Dup mini-gene containing both introns and 
exons is 567bp, 567bp and 559bp for WT, mutant and empty pcDNA-Dup conditions 
respectively.  One explanation of this result is that these fragments are derived from RT-
PCR of unspliced, heteronuclear pcDNA-Dup mini-gene RNA.  After investigating the 
role of plasmid DNA contamination in producing fragments shown in Figure 6, faint 
fragments corresponding to PCR amplification of residual amounts of pcDNA-Dup 
plasmid remaining after DNase I digestion were observed.  However, levels of amplicon 
produced appear to be very low compared to fragments corresponding to pcDNA-Dup 
plasmid of known concentrations loaded into the gel in Figure 7.  Therefore, to account 
for the high intensity fragments observed in Figure 6, the identity of these fragments is 
likely due to RT-PCR of unspliced hnRNA derived from pcDNA-Dup mini-gene rather 
than residual plasmid DNA.  
 
To examine spliced RNA, primers spanning mini-gene exon junctions were designed for 
PCR amplification as described in Chapter 2.1.6.  PCR amplification of cDNA derived 
from pcDNA-Dup using primers specific to mini-gene not containing cassette exon, 
followed by 2% agarose gel electrophoresis, revealed fragments corresponding to the 
expected amplicon size of 209bp in WT BRCA1:c.288C, mutant BRCA1:c.288C>T, and 
empty pcDNA-Dup control conditions (Figure 9, Lane 5, 6 and 4 respectively).  Also, 
PCR amplification of mini-gene containing cassette exon revealed fragments at the 
expected size of 63bp in WT and BRCA1:c.288C>T mutant conditions (Figure 9, Lane 1 
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and 2 respectively).  Therefore, based on this data, both WT and mutant 
BRCA1:c.288C>T show leaky splicing of the cassette exon.  However, the detection of 
DNA fragment corresponding to cassette exon exclusion in the WT condition using exon-
exon spanning primers (Figure 9, Lane 5), and the detection of fragments corresponding 
to mini-gene constructs containing intronic sequences using a T7Pro primer and a primer 
binding the last exon of the mini-gene (Figure 6) suggest that pcDNA-Dup mini-gene 
splicing has poor efficiency and fidelity.  The choice of cell line used in this experiment 
may be a factor affecting transfected plasmid splicing.   
 
The MDA-MB-231 breast cancer cell line was chosen for this study based on a study 
conducted by Morelli et al. (2003) which demonstrated transfection of plasmid derived 
from pcDNA3.1 backbone into MDA-MB-231 cells using FuGene6 transfection reagent 
66
.  However, this group stably transfected cells with plasmid, in contrast to this study in 
which transient transfection was performed to replicate the mini-gene assay performed by 
Tournier et al. (2008) 
47
.  mRNA splicing from a gene transcribed in a genomic context is 
influenced by its epigenetic environment, which consists of histone modification proteins 
that have been demonstrated to associate with splicing factors and influence splicing 
98
.  
Therefore although pcDNA-Dup vector was transfected into MDA-MB-231 cell line as 
supported by the identification of spliced pcDNA-Dup mini-gene cDNA (Figure 9), the 
fidelity and efficiency of splicing of pcDNA-Dup mini-gene as a result of transient 
transfection into MDA-MB-231 cell line may be a cause of PCR amplification of 
unspliced hnRNA (Figure 6) and mini-gene not containing cassette exon in the WT 
condition (Figure 9, Lane 5).  To remediate this, WT pcDNA-Dup mini-gene can be 
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transfected into a variety of cell lines, and the splicing fidelity and efficiency can be 
examined through RNA extraction and RT-PCR to identify a cell line in which splicing is 
efficient and accurate.  This could then be followed by examining plasmids harboring a 
mini-gene containing putative splicing mutations.  In conclusion, the hypothesis that 
BRCA1:c.288C>T affects splicing by abolishing SF2/ASF and SRp40 sites can neither be 
supported nor rejected based on this data as splicing fidelity and efficiency of transiently 
transfected pcDNA-Dup in MDA-MB-231 cell line does not appear to be sufficient. 
 
PCR amplification of cDNA derived from limited amounts of spliced mini-gene RNA 
compared to RNA derived from a genomic context, may skew splice isoform levels with 
respect to endogenous BRCA1 mRNA containing c.288C>T.  Therefore although leaky 
mini-gene cassette exon splicing was observed after RT-PCR of WT and mutant RNA 
using primers spanning exon-exon junctions, if the pool of spliced RNA from which 
these results were derived is small, then the accuracy of this assay as a representation of 
endogenous mRNA splice isoforms encoding BRCA1:c.288C>T transcribed from a 
genomic context may not be high enough for the reliable interpretation of this variant.   
 
The following explanation explains the RT-PCR results of the mini-gene containing 
BRCA1:c.288C>T variant (Figure 9) if they are in fact consistent with what is shown in 
Figure 9 independent of inefficient pcDNA-Dup mini-gene splicing.  Tournier et al. 
(2008) explain that due to a weak 3’ splice site, the cassette exon is not recognized by the 
spliceosome and is therefore excluded in the final processed mRNA transcript unless an 
exonic splicing enhancer element (ESE) is inserted within its sequence, and only a 
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cassette exon harboring a functional ESE will be included in the final transcript
 47
.  Since 
both WT and mutant conditions show cassette exon inclusion, a functional ESE was 
cloned into cassette exon.  This ESE could not have been abolished by the 
BRCA1:c.288C>T variant, because cassette exon appears in both the WT and mutant 
condition.  Examining the 35bp sequence cloned into cassette exon on the ASSEDA 
server as a user defined sequence shows that additional putative ESE elements unaffected 
by the BRCA1:c.288C>T variant are found within this insert, including SRp40 and 
SRp55 binding sites of information content greater than abolished SRp40 site, but lower 
than abolished SF2/ASF binding site.  Therefore it may be possible that one of these ESE 
elements is facilitating cassette exon recognition independent of abolished SF2/ASF and 
SRp40 sites.  However, since DNA fragments consistent with cassette exon exclusion 
were observed in both WT and mutant conditions (Figure 9, Lane 5 and 6 respectively), 
the ESE element responsible for exon inclusion shown in Lane 1 and 2 may not promote 
constitutive exon recognition, and may require additional ESE elements outside of the 
35bp region examined in this mini-gene study.  However, this is speculation.  This could 
be investigated by examining the effects of BRCA1:c.288C>T on whole exon 5 in pCAS2 
mini-gene vector, and looking for constitutive exon inclusion after transient transfection, 
RNA extraction and RT-PCR.  Constitutive exon inclusion would indicate sequence 
motifs outside of the 35bp region surrounding the variant examined in this study could 
facilitate exon recognition by the spliceosome.  Based on RT-PCR analysis, the 
BRCA1:c.288C>T variant predicted using information theory to abolish an SF2/ASF site 
(Ri= 6.6>0.9 bits) and SRp40 site (Ri= 2.6>-2.9 bits) does not appear to affect cassette 
exon recognition by the spliceosome in pcDNA-Dup mini-gene vector.  It may be 
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possible that the putative abolished SF2/ASF site within the cassette exon is not 
functional and does not exist, as the ESEfinder, but not Human Splicing Finder and 
Information theory has indicated (see section 3.1).   
 
Next, PCR amplification cDNA derived from pCAS2 transfection conditions revealed no 
mini-gene specific PCR products corresponding to WT and mutant BRCA1:c.548-16G>A 
and BRCA2:c.7319A>G.  Preliminary control experiments investigating the effectiveness 
of RNA extraction and RT-PCR determined that these experiments were successful 
(Figure 10, 11, 12), therefore RNA extraction and RT-PCR experiments were not the 
cause of no findings.  Furthermore, mini-gene cDNA was PCR amplified under a range 
of annealing temperatures and conditions as described in Chapter 2.1.6.  Therefore 
plasmid transfection and mini-gene expression may be the cause of lack of results.   
 
First looking at mini-gene expression, all mini-genes in this study are under the control of 
a CMV promoter, the most commonly used promoter in mammalian expression vectors 
99
.  Chen et al. (2011) studied the effects of c-Myc-GFP fusion protein, encoded on a 
vector controlled by CMV promoter that was transiently transfected into MDA-MB-231 
cell line, and determined BRCA1 promoter is controlled by c-Myc, and BRCA1 promoter 
activity increases in proportion to amount of vector transfected 
100
.  Also, in the case of 
pcDNA-Dup derived plasmids, spliced mini-gene RNA was detected (Figure 9), therefore 
the CMV promoter is active in MDA-MB-231 cells.  Therefore, it is very unlikely that 
low transcriptional expression of mini-gene plasmid in MDA-MB-231 cell line is due to 
the choice of promoter.  Also, since cells were treated with puromycin prior to 
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harvesting, mini-gene transcripts would not have been degraded due to non-sense 
mediated decay.  Therefore low expression of mini-gene due to promoter choice, or 
degradation of expressed mini-gene due to nonsense-mediated decay are not likely causes 
of lack of fragments corresponding to mini-gene cDNA.  Therefore a more likely cause 
of lack of mini-gene specific RNA is suboptimal transfection.  
 
Although multiple transfection reagent:DNA ratios were performed as recommended in 
the FuGene6 manual, altering the total amount of DNA transfected into each well was not 
optimized.  A total of 3μg of all plasmid DNA (derived from both pcDNA-Dup and 
pCAS2 mini-genes) was transfected into each well containing MDA-MB-231 cells, as 
recommended by the FuGene6 transfection reagent protocol described in Chapter 2.  It 
may be possible that size differences between recombinant pcDNA-Dup vectors (3725bp 
with insert) and pCAS2 vectors (7838bp for BRCA1:c.548-16G>A vector, and 8350bp 
for BRCA2:c.7319A>G vector) result in differences in transfection efficiency, and could 
account for the lower transfection efficiency of pCAS2 derived plasmids, since the 
number of plasmids transfected is less than half of pcDNA-Dup.  To remediate this, a 
gradient of vector DNA (μg) could be transfected into MDA-MB-231 cells to account for 
the larger size of pCAS2 compared to pcDNA-Dup.  
 
One other potential source of reduced transfection efficiency is passage number.  All 
vectors were transfected into cells at the same time, requiring a large number of cells to 
accommodate transfection ratio, and + puromycin conditions.  To lower passage number 
and increase transfection efficiency, only a WT condition would first be transfected to 
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ensure adequate expression and correct splicing.  Once the ideal transfection conditions 
are identified (i.e. plasmid transfection, expression and correct splicing), subsequent 
experiments examining mutant mini-gene sequences could be conducted. Therefore, 
optimizing plasmid DNA amount (μg) during transfection by transfecting a gradient of 
plasmid DNA, while examining only plasmids harboring WT mini-genes, would reduce 
the total number of cells needed for transfection and thus passage number, and could 
increase transfection efficiency and promote mini-gene expression to yield more RNA for 
downstream analyses. 
 
Finally, although a selection agent (G418) was used during cell culture, as described in 
Chapter 2.1.5, to a final concentration of 500ug/mL, as used by Morelli et al. (2003) 
57 
when culturing MDA-MB-231 cells after transfection with pcDNA3.1 backbone plasmid 
containing neomycin resistance gene, it may be possible that cells weren’t exposed to 
drug long enough to kill all cells not harboring plasmid.  The Morelli et al. (2003) study 
examined stable gene transfection and exposed cells to G418 for a longer period of time 
than in this study.  MDA-MB-231 cells were cultured for three days at 500ug/mL of 
G418, followed by 2mg/ml once plasmids were incorporated into the genome, whereas in 
this study, plasmids were transiently transfected to replicate the Tournier et al. (2008) 
study 
47
, and cultured for 48 hours with 500ug/mL G418.  To remediate this, a killing 
curve experiment designed to determine optimal G418 concentration and duration of 
exposure to kill MDA-MB-231 cells not harboring neomycin-resistance gene containing 
plasmid and prevent harvesting cells not containing mini-gene plasmid could be 
performed.  Therefore it may be possible that suboptimal transfection conditions 
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(potentially remediated through transfecting cells of lower passage number under DNA 
concentration gradient) coupled with insufficient exposure to G418 could lead to lack of 
pCAS2 mini-gene RNA.   
4.3 Aim 2: Current molecular diagnostics variant detection 
limitations and expanded sequencing study 
 
A power analysis using BRCA1 and BRCA2 mutation positivity information from the 
Molecular Diagnostics Laboratory indicated that only a fraction of deleterious variants 
are detected when compared to linkage analyses as described in Chapter 2.3 (3.6-35.7% 
vs. 57-100%).  A minimum patient sample size of 13 across all groups defined in Table 6, 
was calculated with 80% power and p<0.05, to be necessary to detect a patient with a 
pathogenic BRCA1 or BRCA2 mutation.  As previous studies have demonstrated that 
pathogenic variants can lie in regions outside of exons and immediate introns 
24,25
, non-
coding regions may harbor deleterious mutations in BRCA1 and BRCA2 that are going 
undetected in routine sequencing.  After coding, non-coding and adjacent intergenic 
regions in seven breast cancer associated genes were sequenced in 21 breast cancer 
patients, 97/152 BRCA1 and BRCA2 SNPs previously detected by the Molecular 
Diagnostics Laboratory were detected in this sequencing study.  The final sequencing run 
achieved an average variant coverage of 47.93x and validated 81/81 BRCA1 and BRCA2 
SNP’s previously detected in coding and adjacent intronic regions by the molecular 
diagnostics lab, compared to the first sequencing run which achieved only a 4.46x 
average variant coverage and a BRCA1 and BRCA2 SNP validation fraction of 1/22.  This 
can be attributed to the protocol alterations described in Chapter 2.2.3, which include the 
use of Agencourt magnetic beads during library preparation, 50bp paired-end reads 
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during sequencing, and an Illumina software upgrade.  This increase in coverage allows 
for sequencing more samples in a single sequencing run in the future, thus increasing 
throughput.   
4.4 Aim 3: Variant prioritization 
 
 
After in silico prioritization of 2871 unique variants detected in all genes over all 
sequencing runs, the number of variants potentially influencing breast cancer etiology as 
predicted using bioinformatics tools was reduced to 19, thus greatly reducing the number 
of putative deleterious variants to examine through future wet-lab functional analyses.  
Of prioritized variants, three were Sanger sequencing validated, none of which were 
previously reported in patients by the molecular diagnostics lab.  Two variants were 
found in the BRCA2 5’ and 3’ UTR (c.-52A>G and c.*369A>G respectively) and were 
predicted by SNPfold and information theory to significantly alter mRNA structure and 
RNA-binding protein binding sites respectively, including abolishing an SNRPA binding 
site (5’ UTR variant) and creating a cryptic SF2/ASF binding site (3’ UTR variant) 
(Table 12).  Abolishing an SNRPA binding site could affect splicing between the 5’ UTR 
and first exon of BRCA2 since this variant is located 12bp upstream of a natural donor 
site and the U1 snRNP (SNRPA) is known to bind the donor site.  The inability of the 
spliceosome to recognize the donor site of the 5’ UTR could prevent splicing of the 5’ 
UTR and exon 1 intervening intron and prevent 5’ UTR from being included in the final 
transcript, thus affecting mRNA stability, and translation initiation.  However, since this 
variant is reported in dbSNP to have an alternate allele population frequency of 0.156, it 
is unlikely that it alone is a causative variant in breast cancer etiology due to its high 
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prevalence in the population.  However obtaining genotype data for this SNP in a greater 
disease patient sample size in the future would allow one to construct an OR value for 
this SNP when comparing it to healthy control SNP information from dbSNP.  This is 
also true of the BRCA1 3’ UTR, c.*369A>G (rs7334543; alternate allele population 
frequency of 0.231).  The UTRs in each patient DNA sample harboring these variants 
were PCR amplified and sent to a collaborator at UNC (Alain Laederach) for SHAPE 
analysis to validate SNPfold predictions on mRNA structure.   
 
At the time of writing this thesis, in vitro analyses of 85 human RNA-binding proteins 
(RBP) were conducted by Ray et al. (2013) to examine sequence recognition specificity 
101
.  RNA-binding protein sequence motif conservation was examined in three mRNA 
regulatory regions, including: a) 5’ and b) 3’ UTRs, and c) alternatively spliced exons 
and flanking introns.  Approximately two thirds of RBPs analyzed (104 of 165) showed a 
high degree of conservation in at least one of these three regulatory regions.  The 
majority of motifs in most RBP families are found in multiple regulatory regions (38 out 
of 49 RBP families), suggesting RNA-binding protein multifunctionality.  Of all RBP 
isomers analyzed, the sequence recognition motifs of 20 of them were scanned in the 
UTR regions in this thesis for information content changes as a result of a genetic variant.  
Of the 20 RBPBS examined in this thesis also reported in Ray et al. (2013), three are 
associated with stabilizing 3’ UTR mRNA (PUM2, EIF4B, ELAVL1) and three promote 
3’ UTR mRNA instability (SRSF1/2/9) according to in vitro RBP binding experiments, 
and mRNA stability experiments correlating RBP and target gene expression conducted 
on a set of 34 human tissues and cell lines (Ray et al., 2013) 
101
.  
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Also, one putative splicing variant located 66 nucleotides upstream of an intron-exon 
junction in BRCA2 (c.197T>C) not previously detected by the Molecular Diagnostics 
Laboratory in these patients was identified and validated by Sanger sequencing.  This 
variant is predicted to result in strengthening a cryptic acceptor site (Ri = 0.63> 1.75 bits) 
to approximately the same information content as the corresponding natural site (1.72 
bits).  If the spliceosome binds this site, exon could be extended by 66 nucleotides 
upstream.  However, this variant is a SNP (rs4942486) with high alternate allele 
population frequency (0.468) and therefore likely not influential in disease etiology.  
 
Two putative heat shock factor 1 (HSF1) TFBS inactivating variants, one in CDH1 
(c.48+76C>T), the other in CHEK2 (c.-346T>C), both within 300bp of the transcription 
start site were prioritized (see Table 11).  HSF1 function has been shown to support 
aberrant proliferation and survival of a variety of human cell lines, including both breast 
tumor and mammary epithelial lines 
102
. Dai et al. found that small hairpin RNA 
mediated knockdown of HSF1 in human mammary epithelial cells had only a minimal 
impact on cell viability (~90% viable cells remaining after 4 days), whereas the number 
of viable tumorigenic mammary epithelial cells subjected to the same shRNA-mediated 
HSF1 knockdown greatly decreased in comparison (<20% viable cells remaining after 4 
days) 
69
.  This group concluded that while HSF1 can enhance survival and longevity 
under most conditions, tumor cell proliferation and survival is dependent on HSF1 
activity.  Therefore in the context of this study, inactivating mutations in HSF1 binding 
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sites within the CDH1 and CHEK2 promoter may be more influential in women with 
breast cancer versus women without breast cancer, and may linked with better prognosis.   
 
Another putative TFBS inactivating variant was found in a BCLAF binding site in 
CHEK2 (c.-346T>C).  The Bcl-associated factor 1 transcription factor (BCLAF) has been 
shown to be involved in tumor suppression.  A study conducted by Kasof et al. (1999) 
demonstrated that overexpression of BCLAF in HeLa cells suppresses transcription 
induced apoptosis 
103
.  A Northern blot analysis in several human tumor cell lines 
indicated that the chromosomal region encoding BCLAF is deleted in some tumor types.   
Therefore it is conceivable that abolishing a strong BCLAF binding site in CHEK2, 
which encodes a kinase involved in the apoptosis pathway, may promote oncogenesis.  
Another TFBS with a large information content change as a result of a variant in CDH1 
was TCF7L2 (c.163+1880G>T) Δ Ri 10.3>1.2 bits).  An association study by Connor et 
al. (2012) has shown that several SNPs in the TCF7L2 gene are linked to increased breast 
cancer risk 
104
, although the underlying mechanisms associated with breast cancer 
etiology are unclear.  ChIP-seq analysis performed by Frietze et al. (2012), has shown it 
to be expressed in the breast cancer cell line MCF7, and bind to enhancer regions of 
many genes 
105
.  Therefore although SNPs in TCF7L2 have been associated with breast 
cancer, and ChIP-seq analyses have demonstrated that it is expressed in breast cancer cell 
lines and binds to enhancer regions, it is difficult to predict what the effects of an 
abolished TCF7L2 site would have on breast cancer etiology.  Variants within these 
TFBS were not Sanger sequencing validated. 
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Finally one protein truncation mutation was identified in BRCA1 previously by the 
Molecular Diagnostics Laboratory (c.5136G>A, p.W1712Stop), and used as a positive 
control, was confirmed in this study.  Additionally, a second putative protein truncation 
mutation in ATM was identified in this study (c.7051G>T), although its coverage value is 
12 and needs to be Sanger sequencing validated. 
 
Therefore, after examining prioritized, Sanger sequencing validated variants, it is 
possible that two are influential in disease etiology, both residing in BRCA2, one in the 5’ 
UTR, the other in the 3’UTR.   However, in silico predictions need to be validated 
through SHAPE analysis and ultimately an additional functional analysis relating 
structural changes to BRCA2 transcript stability and RNA-binding protein binding.  
Increasing sample throughput as mentioned earlier would allow for organizing patient 
samples according to family history as outlined in Table 6, as well as increasing the 
number of patient DNA sequenced in a single sequencing run, thus bringing the number 
of sequenced patients in each group to the threshold predicted using the power analysis 
needed to detect a deleterious variant in BRCA1 and BRCA2. 
4.5 Project limitations 
 
 
PCR amplification of unsliced hnRNA transcribed from pcDNA-Dup mini-gene (Figure 
6) and WT pcDNA-Dup mini-gene not containing cassette exon suggests improper 
splicing of transiently transfected pcDNA-Dup plasmid in MDA-MB-231 cell line.  
Examining RNA from WT pcDNA-Dup plasmid transfected into multiple cell lines may 
identify a cell line in which mini-gene splicing is correct and efficient, which can then be 
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used to examine plasmids containing mutant mini-gene sequences.  Suboptimal DNA 
concentration, passage number and exposure to G418 selection agent during transfection 
of pCAS2 recombinant plasmids may account for low transfection efficiency, which 
resulted in no fragments corresponding to mini-gene cDNA.  Determining optimal G418 
selection agent by performing a “killing curve”, while reducing passage number by 
examining mutations individually and transfecting using a gradient of DNA may identify 
optimal transfection conditions to ascertain the effects of BRCA1:c.548-16G>A and 
BRCA2:c.7319A>G variants on mini-gene splicing.  
 
 
For the patient breast cancer associated gene sequencing study, of the 19 prioritized 
variants, only three were Sanger sequencing validated.  This can be attributed to two 
factors, low coverage and read alignment error.  Meynert A.M. et al. (2013) 
106
 examined 
minimum read depths required for single nucleotide variant detection in DNA enriched 
through a variety of commercial capture arrays such as Agilent and Nimblegen, which 
varied from 19.7+0.9 fold coverage to 45.6+4.2 fold coverage for 95% sensitivity for 
heterozygous mutations.  Eleven of nineteen prioritized variants in this study had a 
minimum read depth of <10x, all of which were not Sanger sequencing validated.  
 
In contrast, some high coverage variants were also not Sanger sequencing validated, 
including the putative TFBS variant CHEK2:c.-346T>C, which had 69x coverage in one 
patient and 206x coverage in another.  This can be attributed to a read alignment error. 
Limitations in DNA shearing can result in DNA fragments containing both unique 
sequences hybridizing to probe, and low complexity regions at the ends of the fragment.  
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RNA probes will hybridize to single-copy region on DNA fragment containing low-
complexity regions on the fragment ends, which are subsequently enriched and paired-
end sequenced, leading to misalignment to the genome and resulting in false positive 
variant calling.  Unique regions within segmental duplicons can also be captured and 
misaligned to the genome, resulting in false positive variant calling.  It was discovered 
that multiple patients carried several of the same “novel” exonic mutations in CHEK2, 
after investigating further, it was discovered that these mutations lie in a pseudogene 
spreading across exons 10-14 within a segmental duplicon that maps to chromosome 15.  
A total of twelve segmental duplicons were found in a ~21kb region in CHEK2 
(chr22:g.29,071,654-29,092,380).  Therefore, false positive variant calls within this 
region may be attributed to probe hybridizing to off-target chromosomes, which is 
subsequently sequenced and incorrectly aligned to CHEK2.  Therefore it is critical to 
validate variants called within segmental duplicon regions through Sanger sequencing to 
ensure they are not false positives due to alignment errors.   
 
Finally, a variant with moderate coverage, the putative TFBS variant, ATM:c.-365C>G  
(29x coverage, 13 reads calling alternate allele) was not Sanger sequencing validated.  
Examining read information on the Integrated Genomics Viewer (IGV; Robinson J.T. et 
al. 2011) revealed that the 13 reads calling the alternate allele had low phred base quality 
scores (all <2) upstream of the variant, which itself had a phred base quality score of 213.  
Therefore a false positive variant call was generated through overall poor read quality, 
despite the variant base itself passing the stand_call_conf filter threshold of 30 during 
GATK variant calling. 
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No putative deleterious variants were prioritized in low to moderate penetrant genes.  
This may be attributed to two causes, including small sample size and sample selection.  
The criteria for molecular diagnostic sequencing of high penetrant breast cancer 
associated gene BRCA1 and BRCA2 is a strong family history of breast as defined on 
page two of the, “Ontario Cancer Genetic Testing Program” requisition form 
(http://www.lhsc.on.ca/lab/molegen/brca_req.pdf).  Therefore sequencing low to 
moderate penetrant breast cancer associated genes in a cohort of patients with a high 
incidence of breast cancer may skew results in favor of variant detection in the high 
penetrant breast cancer associated genes BRCA1 and BRCA2.  To detect variants in low 
to moderate penetrant genes, it may be necessary to identify women with lower incidence 
of breast cancer family history than that described in the “Ontario Cancer Genetic testing 
Program requisition form”.   Alternatively, there may be other high penetrant breast 
cancer associated variants lying outside of the high penetrant breast cancer associated 
genes BRCA1 and BRCA2 that are in regions not examined in this study that contribute to 
breast cancer risk.  Lalloo F. and Evans D.G. (2012) estimate that ~61% of the familial 
component of breast cancer is linked to unidentified regions in the genome which could 
harbor high penetrant variants not probed for in this experiment 
7
.  
4.5 Conclusion and implications 
 
 
The limitations of routine diagnostic sequencing in detecting pathogenic DNA variants in 
individuals with or at risk of breast cancer warrants deeper probing into non-coding and 
intergenic regions in BRCA1 and BRCA2 as well as other genes associated with familial 
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breast cancer, such as ATM, CDH1, CHEK2, PALB2 and TP53.  Library DNA samples 
prepared with Agencourt Magnetic beads, show less sample loss from column and gel 
purification steps as well as sample transferring, and result in increased coverage and 
ultimately, more reliable variant calling.  Since the vast majority of true variants detected 
in large sequencing studies are polymorphisms or variants of unknown significance 
97,11
 , 
it is necessary to first prioritize variants in silico for effects on cellular processes integral 
in healthy gene expression such as: splicing, transcription factor binding, 5’ and 3’ UTR 
structure and mRNA binding protein binding, amino acid changes and miRNA binding.  
All in silico prioritized variants need to be examined for read alignment errors prior to 
Sanger sequencing to reduce the incidence of false positive variant calls as discussed in 
Chapter 4.4.  After Sanger validation, prioritized variants need to be examined in the 
literature to ascertain clinical significance, if unknown, it is necessary to perform 
functional analyses to validate the effects of the variant on the process in question 
through assays such as those described in Chapter 1.7 before the variant can be classified 
as deleterious.   
 
This project provides a workflow for variant detection in several breast cancer associated 
genes of varying penetrance, as well as an in silico framework that prioritizes variants 
predicted to affect a variety of cellular processes involved in WT gene expression for 
downstream function analyses.  Sanger validated variants likely most influential in 
disease etiology, undetected by the molecular diagnostics lab, have been submitted to a 
collaborator at UNC (Dr. Alain Laederach) for functional analysis to validate in silico 
prioritization.  Overall, this work can improve variant detection in individuals with or at 
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risk of breast cancer in which routine sequencing revealed no deleterious findings and 
impact patient genetic counseling and quality of care. 
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